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ABSTRACT 
PAMELA WHITNEY KLEIN: An Evaluation of an Expanded HIV Testing Program in North 
Carolina Sexually-Transmitted Disease Clinics 
(Under the direction of Dr. William C. Miller and Dr. Peter A. Leone) 
 
 Over 20% of the 1.1 million persons infected with HIV in the United States are 
unaware of their HIV infection; these persons contribute to approximately 50% of new 
transmission events each year. To address this problem, the Centers for Disease Control 
and Prevention released recommendations supporting routine, opt-out HIV testing in clinical 
settings. We conducted a before-after intervention analysis of a routine, opt-out HIV testing 
program implemented in North Carolina sexually transmitted disease (STD) clinics.  
The study population included all adult North Carolina residents who were tested for 
HIV in any of the 102 North Carolina STD clinics from July 1, 2005 through June 30, 2011. 
Exposure was dichotomized at the date of intervention implementation on November 1, 
2007. Three primary outcomes were considered: (1) HIV testing, as absolute counts and 
rate per 100,000 population; (2) detection of new HIV-infected persons, as absolute counts 
and HIV-positivity per 1000 tests; and (3) progression to AIDS within 12 months of HIV 
diagnosis. Interrupted time series analyses were used to examine trends in HIV testing and 
case detection over the study period; Poisson regression and multilevel regression models 
with county-specific random intercept terms were used to evaluate the overall impact of the 
intervention. 
Pre-intervention, 426 new HIV-infected cases were identified from 128,029 tests 
(0.33%), whereas 816 new HIV-infected cases were found from 274,745 tests post-
intervention (0.30%). Pre-intervention, HIV testing increased by 55 tests per month (95% 
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confidence interval [CI]: 41, 72), but only increased by 34 tests per month (95% CI: 26, 42) 
post-intervention. A slight pre-intervention decline in the monthly rate of case detection was 
mitigated by the intervention (mean difference in HIV-positivity=0.01; 95% CI: -0.02, 0.05). 
Overall, no association was observed between the introduction of the intervention and risk of 
progression to AIDS within 12 months of initial HIV diagnosis (risk ratio=1.05, 95% CI: 0.77, 
1.43). 
 The impact of a routine, opt-out HIV testing program in North Carolina STD clinics 
was minimal. Persons not traditionally targeted for HIV testing, particularly women, 
experienced the greatest benefit. HIV prevention interventions should be continually 
evaluated for program efficacy. 
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CHAPTER 1: SPECIFIC AIMS 
 
In 2006, the Centers for Disease Control and Prevention (CDC) recommended 
routine, opt-out human immunodeficiency virus (HIV) testing in clinical settings and 
launched a funding initiative to support the implementation of expanded HIV testing 
programs that focus on routine screening.1,2 Approximately 20% of persons infected with 
HIV are unaware of their HIV-infected status; disease transmission from these individuals 
accounts for 50% of new HIV infections in the United States.3-5 From 2007 through 2010, the 
CDC initiative funded 2.8 million HIV tests and identified over 18,000 new HIV-infected 
cases.2 However, these newly-diagnosed persons represent only a fraction of the 
approximately 150,000 new transmission events that occurred in the United States during 
the same time period.6 
Although, routine, opt-out HIV testing programs have increased HIV testing, the 
evidence is inconclusive regarding the impact of these programs on HIV case detection and 
HIV-related clinical outcomes (Table A1.2).7-13 To date, presentation of data on these 
programs are predominated by descriptive analyses that fail to compare the intervention to 
any control group (Table A1.1). Evaluations that used control groups have focused on 
clinical facilities in major metropolitan centers, limiting generalizability the Southeastern 
United States, which bears a disproportionate burden of HIV infection.14 Due to small 
numbers and inadequate statistical methods, the public health importance of existing 
evaluations is questionable. 
Using a before-after study design, we assessed the impact of a routine, opt-out 
expanded HIV testing program implemented in North Carolina sexually-transmitted disease 
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(STD) clinics on: HIV testing, the new diagnosis HIV-infected cases, and risk of progression 
to acquired immunodeficiency syndrome (AIDS) shortly after HIV diagnosis. 
 
Aim 1: Estimate the impact of a routine, opt-out expanded HIV testing program on HIV 
testing patterns and the detection of new HIV-infected cases in North Carolina STD 
clinics 
Hypothesis: Both the number and rate of HIV testing and new HIV-infected cases were 
higher post-intervention (post-intervention period: November 1, 2007 – June 30, 2011) than 
pre-intervention (pre-intervention period; July 1, 2005 – October 31, 2007). 
Overview: To address the inconclusive data available regarding the detection of HIV-
infected persons with an expanded HIV testing program, we used a before-after intervention 
analysis of persons tested for HIV in North Carolina STD clinics. Interrupted time series 
analyses were used to assess the change in outcome trends over time, while accounting for 
underlying temporal correlation. Multilevel regression models were used to evaluate the 
overall impact of the intervention and account for patient clustering within STD clinics. 
 
Aim 2: Estimate the impact of a routine, opt-out expanded HIV testing program on the 
risk of progression to AIDS within 12 months of initial HIV diagnosis among newly-
identified HIV-infected cases detected in North Carolina STD clinics 
Hypothesis: New HIV-infected cases identified post-intervention (post-intervention period: 
November 1, 2007 – June 30, 2011) had a lower risk of progression to AIDS within 12 
months of initial HIV diagnosis new HIV-infected cases identified pre-intervention (pre-
intervention period: July 1, 2005 – October 31, 2007). 
Overview: A large proportion of new HIV-infected cases present as “late diagnoses”, cases 
with advanced HIV disease that are diagnosed with AIDS within one year of their HIV 
diagnosis.15,16 If routine, opt-out HIV testing programs successfully identify individuals earlier 
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in their disease progression, fewer patients would present at late stages of infection. We 
used a before-after intervention analysis to compare the risk of progression to AIDS among 
new HIV-infected cases diagnosed in North Carolina STD clinics before and after the 
implementation of a routine, opt-out HIV testing intervention. Multilevel regression models 
were used to evaluate the overall impact of the intervention and account for patient 
clustering within STD clinics. 
 
Efficient HIV testing strategies are essential to engage HIV-infected persons in HIV-
specific medical care, which subsequently prevents HIV-related morbidity and mortality, as 
well as the further disease transmission.3,17-23 Although routine HIV testing is feasible and 
acceptable, its impact on HIV case detection and risk of progression to AIDS is unclear 
(Table A1.1, Table A1.2). This study used a before-after intervention analysis study design 
in STD clinics to examine the statewide impact of a routine, opt-out expanded HIV testing 
program. Routine, opt-out HIV testing programs must be rigorously evaluated to ascertain 
the extent to which the intervention attains programmatic goals. 
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CHAPTER 2: INTRODUCTION 
 
In 2006, in an effort to increase population awareness of HIV status and, eventually 
reduce HIV transmission in the United States, the CDC released recommendations for 
routine, opt-out HIV screening in clinical settings.1 Expanded HIV testing programs showed 
the acceptability and feasibility of routine HIV screening in clinical settings (Table A1.1).7,9,10 
However, the ability of expanded HIV testing programs to adequately address the specific 
goals of the CDC’s recommendations remained unclear. 
 
Importance of HIV Testing 
HIV testing is the gateway to accessing the continuum of HIV care, which includes 
linkage, engagement, and retention in HIV-specific medical care (Figure 2.1).3 HIV care, 
especially treatment with antiretroviral therapy, is important from both the personal and 
public health perspectives. Once engaged in HIV care, patients can be treated with 
antiretroviral medication to achieve viral load suppression.17-19 Patients with suppressed viral 
loads are less likely to experience negative health outcomes, such as opportunistic 
infections, and are more likely to have increased life expectancy and improved quality of life. 
Of the 1.1 million persons believed to be living with HIV in the United States, 21% 
are not aware of their HIV-infected status.3 These HIV-infected persons who are unaware of 
their status contribute to approximately 50% of all new HIV transmission events in the 
United States.4,5 Increased HIV transmission from persons who are unaware of their HIV-
infected status can be attributed a lack of safe sex practices and, as HIV therapy reduces 
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the likelihood of HIV transmission, failure to engage in HIV care.20-25 Without case detection 
and engagement HIV care, suppression is not possible. 
 
History and Rationale for CDC Recommendations 
The importance of HIV testing to both the treatment of HIV-infected persons and 
preventing disease transmission has been well-recognized.1 However, shortcomings mire 
current HIV testing strategies. Before the CDC recommendations, most HIV testing 
protocols called for diagnostic or risk-based HIV testing (Table 2.1).  
Diagnostic testing screens patients because of clinical signs and/or symptoms 
commensurate with advanced HIV infection (Figure 2.2).26 HIV is largely asymptomatic 
before progression to AIDS; the asymptomatic phase of infection lasts approximately 10 
years.27,28 Therefore, diagnostic testing based on symptoms of opportunistic infections 
detects people late in the course of their infection. In addition to poor health outcomes for 
the HIV-infected individual, if the person has been unaware of his/her infection for many 
years, there is an increased likelihood that this person contributed to further disease 
transmission.4  
Since many years can pass between seroconversion and the development of clinical 
symptoms, a person presenting late for HIV testing may have had multiple prior contacts 
with medical providers without an HIV testing encounter. Among patients diagnosed with 
AIDS within 1 year of their initial HIV diagnosis in South Carolina, 73% made at least one 
visit to a health-care facility before their diagnosing HIV test.29 Late diagnoses and these 
missed opportunities for HIV testing highlight the limitations of diagnostic HIV testing 
strategies. Although highly specific for case detection, diagnostic testing is an inadequate 
public health intervention. 
Targeted HIV tested based on risk factors, or “risk-based HIV testing”, identifies 
patients based on risk factors associated with HIV transmission.26 Usually, a formal risk 
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assessment is conducted by an HIV counselor. HIV counselors inquire about a patient’s 
sexual history and practices, past drug use, trading sex for drugs or money, incarceration, or 
history of other sexually transmitted diseases. The goal of risk-based HIV testing is to 
identify HIV-infected persons before they present with AIDS-related symptoms, while 
concentrating resources on patients who are at high risk for HIV acquisition.30  
Testing only patients with prescribed risk factors further stigmatizes the disease and 
the at-risk patient population.31-33 Risk assessments often misrepresent a person’s true risk 
profile; persons may be hesitant to report risky behaviors, such as multiple sexual partners, 
same-gender sexual interactions (especially men who have sex with men), or drug use.30,34-
39 Additionally, many persons with HIV do not belong to traditional high-risk groups, limiting 
the utility of risk assessments to identify HIV-infected persons.30,40 Misrepresentation of a 
person’s true risk profile limits the utility of the risk assessment and can lead to decreased 
HIV testing of truly high-risk persons. 
The shortcomings of both diagnostic and risk-based HIV testing led to the 
investigation of alternative HIV testing strategies through mathematical simulations and 
cost-effectiveness models. A “test and treat” HIV prevention protocol, in which all persons in 
a population are regularly tested for HIV and all HIV-infected persons are provided with 
antiretroviral therapy, was explored in a mathematical model. 41 This model demonstrated 
the potential for the “test and treat” paradigm to significantly halt the HIV epidemic in South 
Africa. 
To examine the economic feasibility of a universal HIV testing strategy in the United 
States, incremental cost-effectiveness analyses were used to compare routine HIV 
screening with diagnostic testing. These economic analyses found routine HIV screening to 
be cost-effective, costing approximately $40,000 per quality-adjusted life year (QALY), 
compared with diagnostic testing.42-44 The generally accepted threshold for a cost-effective 
of medical screening procedures is below $50,000/QALY.45 Because of improved quality of 
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life and reduced medical bills from opportunistic infections, as well as prevention of 
secondary disease transmission, routine HIV screening results in a low cost per QALY.46 
 
CDC Recommendations for Routine HIV Screening 
The CDC released recommendations for routine HIV screening in clinical settings to 
reach the population of HIV-infected persons who present late for HIV testing.1 These 
recommendations were further supported by the limitations of diagnostic and risk-based 
testing, the potential of the “test and treat” paradigm to impede the HIV epidemic, and the 
estimated cost-effectiveness of routine HIV screening. The recommendations urged routine, 
opt-out HIV screening in clinical settings where the prevalence of infection was at least 
0.1%.1 The primary goals of the CDC recommendations were to (a) increase HIV testing, (b) 
detect previously unaware HIV-infected persons, and (c) identify HIV-infected persons 
earlier in the course of their HIV infection, compared with diagnostic or risk-based HIV 
testing protocols. 
The CDC disbursed funding to city and state health departments with high HIV/AIDS 
burdens to implement expanded HIV testing programs in clinical settings. Since the 
introduction of this funding initiative in 2007, clinical setting personnel have performed 2.8 
million HIV tests and identified 18,000 new HIV-infected cases (0.7% positivity).2 However, 
these new diagnoses only represent a fraction of the estimated 150,000 new HIV 
transmission events during the same period.6 
 
Existing Literature Neglects Program Goals and Lacks Generalizability 
Since the release of the CDC recommendations in 2006, over 50 peer-reviewed 
publications have described expanded HIV testing programs in clinical settings (Table A1.1). 
The majority of publications are solely descriptive, demonstrating the feasibility and 
acceptability of expanded HIV testing programs. While feasibility and acceptability are 
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crucial to the success of expanded HIV testing programs, they do not directly address the 
goals of the CDC’s recommendations. Clinical measures, such as concurrent AIDS 
diagnosis, CD4 counts, or viral load measurements, are only included in a small fraction of 
publications.7-9,11-13,47-56 Comparison between publications is challenging because the 
programs described vary in their scope and HIV testing protocols (Table A1.1). 
Over half (22/55) of the publications detail HIV testing programs in emergency 
departments. This focus on emergency departments limits the generalizability of these 
studies to similar acute care settings (Table A1.1). Emergency departments act as access 
points for many uninsured persons who are at increased risk for HIV acquisition, but they 
represent a selected subset of the overall US health-care seeking population.57,58 Other 
expanded HIV testing programs have been described in community health centers (3), 
prisons/jails (6), dental clinics (1), STD clinics (5), primary care settings (2), hospital 
inpatient settings (5), and health care systems (4). 
 
Contradictory Evidence from Comparison Studies 
In contrast with the plethora of descriptive analyses, only 19 of these program 
evaluations included a comparison group (Table A1.2). The majority of evaluations with 
comparison groups showed an increased number of HIV tests performed with the 
introduction of the expanded HIV testing program. However, the magnitude of this increase 
varied based on the clinical setting. In most clinical settings, very little HIV testing was done 
prior to the intervention, so the number of HIV tests conducted could increase 
greatly.11,49,56,59-62 In other clinical settings with high-risk patient populations, like STD clinics, 
the baseline rate of HIV testing was so high that the maximum benefit from an HIV testing 
program was minimal.63 
Data indicating the ability of expanded HIV testing programs to detect more HIV-
infected persons, one of the CDC’s primary goals, are contradictory.  Expanded HIV testing 
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programs were associated with an increase in HIV case detection in many clinical settings 
(Table A1.2). However, some sites showed a decrease or no change in the proportion of 
patients testing positive for HIV.7,8,11,12,49,56,62,64,65 The investigator’s choice of outcome used 
to assess program yield, either the number of newly identified HIV-infected persons or the 
positivity proportion, can change the interpretation of a programs’ ability to identify new HIV- 
infected persons. For example, an Veteran’s Administration health system in Washington, 
DC observed that the number of HIV- infected persons identified increased from 47 to 69 
with the introduction of routine HIV screening, yet the positivity proportion decreased from 
1.5% to 1.1%.62 This discrepancy can be attributed to the large increase in HIV testing that 
was needed to detect additional HIV cases. 
These analyses with comparison groups are often restricted to a single clinical 
facility, which limits the size of the population under study. Because HIV is a rare infection in 
the general population (1% HIV prevalence is considered very high), very few new HIV- 
infected cases were identified in these single-facility HIV testing programs (Table A1.2). The 
public health significance of findings based on such small numbers is questionable. 
Additionally, the focus on single clinical facilities limits the generalizability of the findings to 
similar settings – most commonly, urban emergency departments with limited pre-
intervention HIV testing. One must question the applicability of these findings to other 
clinical settings or more rural areas of the United States. 
Few program evaluations consider the immunologic state of newly-diagnosed 
persons at diagnosis or the timing of progression to AIDS.7,8,11,13 Ecologic data from New 
York City and Rhode Island suggested an improvement in the immunologic status of newly-
diagnosed HIV-infected persons with the introduction of programs or policies that facilitated 
routine, opt-out HIV testing.66,67 However, these studies did not examine the individual-level 
impact of interventions, but rather the association between a system-wide change (New 
York City: “Bronx Knows” HIV testing campaign; Rhode Island: a legislative amendment 
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allowing routine, opt-out HIV testing) and the immunologic status of a sample of persons in 
the catchment area of the system-wide change (New York City: Bronx HIV surveillance 
records; Rhode Island: clinical data on persons attending an HIV clinic). 
Other program evaluations were based in emergency departments in major 
metropolitan centers. In a study from Oakland, California, the proportion of persons 
diagnosed with AIDS at the time of their HIV diagnosis (CD4 ≤ 200) was 48% during an 
experimental opt-out HIV testing program, compared with 25% in the opt-in protocol 
comparison group.13 However, when the same emergency department changed from a 
diagnostic-based testing program to routine screening, the average CD4 cell count at 
diagnosis increased from 99 cells/uL to 356 cells/uL.11 In an emergency departments in 
Denver, Colorado, and Chicago, Illinois, CD4 cell counts increased with a change from 
diagnostic-based HIV testing to routine, opt-out screening.7,8  
Although these programs examined clinical outcomes, they could only assess 
immunologic status at diagnosis and not progression to an immune-compromised state over 
time. Medical records were restricted to the single facility that performed the diagnosing HIV 
test; data were not linked to surveillance records and HIV- infected persons could not be 
tracked for engagement in HIV care in other clinical settings. As discussed previously, HIV is 
a rare outcome and the sample sizes of these evaluations are inadequate to confidently 
describe any potential public health impact. In combination, these studies only examined 90 
HIV-infected persons pre-intervention and 134 HIV-infected persons post-intervention.7,8,11,13 
 
Gaps in the Comparison Study Literature 
Further research is needed to critically evaluate expanded HIV testing programs 
using a valid comparison group to identify if expanded HIV testing programs are indeed 
meeting CDC goals. The number and proportion of HIV- infected patients must be 
measured, as well as a clinical marker of disease state at diagnosis. In addition, the current 
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focus on clinical settings with limited HIV testing pre-intervention, such as emergency 
departments, sets unrealistic expectations. The maximum potential of an intervention in a 
clinical setting is dictated by the clinic’s size and capacity. The potential increase in HIV 
testing in clinical settings with low pre-intervention levels of HIV testing is much greater than 
could possibly be observed in clinical settings with high pre-intervention levels of testing. As 
clinical settings with a high proportion of at-risk patients would, presumably, already have 
some HIV testing capacity, a greater emphasis should be placed on the incremental impact 
of HIV testing programs in these settings. 
Although useful to indicate the ability of routine HIV testing programs to perform a 
greater number of HIV tests, the current literature does not provide consistent evidence that 
these programs have led to more HIV- infected persons are being identified, or identified 
any earlier in the course of infection. 
 
Southeastern United States is an Area of High HIV Burden 
The geographical and social context of an HIV epidemic is crucial to consider when 
planning HIV prevention efforts. Following the “test and treat” simulation model based in 
South Africa, the gross differences between the South African and American HIV epidemics 
necessitated inquiry as to the translation of the model’s results to the American context.68-71 
United States-based simulation models identified the potential for “test and treat” 
interventions to reduce transmission, although the extent of that reduction varied. However, 
the US epidemic also experiences regional variation, which is often ignored in nationally-
aggregated HIV prevention data, including official reports of the CDC’s expanded HIV 
testing funding initiative.2  
In particular, the bulk of the expanded HIV testing literature focuses on major 
metropolitan centers or highly urbanized regions of the northern part of the United States. A 
program that is efficient in New York City or San Francisco may not be as successful in 
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other, more rural areas of the country. Only 6 publications cite expanded HIV testing 
programs in the Southeastern United States.54,61,72-75 
The Southeastern US experiences some of the country’s highest rates of HIV 
infection (Figure 2.3).14 In the early 2000s, the number of new AIDS cases in the Deep 
South increased 35.6%, compared with an increase of only 5.6% in other states.76 Given 
issues with late diagnosis and potential transmission of HIV infection when the disease is 
left untreated, the disproportionate burden of HIV infection born by the Southeastern United 
States is not surprising.  
In North Carolina, an estimated 35,000 persons are living with HIV/AIDS, including 
7,000 who may be unaware of their infection.40 Approximately 1,500 new HIV cases are 
detected annually. North Carolina has the 8th highest rate of new HIV diagnoses at 23.8 
cases per 100,000 (US rate 21.1 per 100,000) and the 13th highest rate of adults and 
adolescents living with HIV infection at 294.0 per 100,000 (US rate = 337.5 per 100,000). 
North Carolina also has the 11th highest rate of AIDS diagnoses at 11.6 per 100,000 (US 
rate = 11.2 per 100,000).  
The prevalence of many poor health indicators is higher in the Southeastern United 
States than other regions of the country; many of these poor health indicators can facilitate, 
directly or indirectly, HIV transmission. These poor health indicators include: high levels of 
poverty, inconsistent availability and quality of health care services, and a high prevalence 
of STDs and other comorbid conditions.76 
Racial/ethnic disparities in the HIV-infected population are more pronounced in the 
Southeast than in other regions of the country.14 In North Carolina non-Hispanic blacks 
account for 22% of the state’s population, but represent over 66% of the state’s HIV case 
burden.40 In 2010, the rate of HIV diagnoses was 94 cases/100,000 among non-Hispanic 
black men, compared with 11.6 cases/100,000 among non-Hispanic white men. Similar 
disparities are observed in women. These disparities can be attributed, in part, to high rates 
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of incarceration among non-Hispanic black men, which disrupts the normal gender ratios of 
communities, and concurrent sexual relationships.77-80 
Acute infection is a major concern in areas like North Carolina, where transmission is 
not solely driven by persons with established infection, but by newly infected individuals. In 
the early 2000s, an outbreak of acute HIV infection among young, black men who have sex 
with men was identified in the college student population in North Carolina.81 Since 2003, 
176 acute cases of HIV have been identified. Eighty percent of these cases were male and 
69% were black; he median age of infection was 25 years.40 Acute HIV infection is indicative 
of a more recent, evolving epidemic, rather than an epidemic of more established, chronic 
infection seen in many metropolitan centers. 
The rural nature of much of the Southeastern United States also complicates HIV 
prevention efforts. Persons living in rural areas are more likely to experience stigma related 
to HIV infection, which could adversely impact the success of HIV testing efforts and 
disclosure of HIV status to sexual partners.82-85 Persons living in rural areas are more likely 
to present with late diagnosis of HIV and experience barriers in accessing HIV care.82,86-90 
These barriers could be related to social stigma or structural barriers, such as a lack of 
transportation to HIV care specialists. 
 
The Role of HIV Testing in Current HIV Treatment Paradigms 
With the advancement of new HIV care paradigms like “treatment as prevention” 
after the successful HIV Prevention Trials Network Study 052, HIV testing’s role as the 
access point to the HIV treatment cascade is of even greater importance.24 Yet, the ability of 
routine HIV screening to increase detection of HIV-infected persons and identify HIV-
infected persons early in the course of their infection is unclear. While proof of concept has 
been shown in experimental environments, the effectiveness of routine HIV screening in all 
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geographic regions of the US has not yet been demonstrated.7 Through this study, we aim 
to address the impact of routine, opt-out HIV testing in a real-world environment. 
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Tables and Figures 
Figure 2.1: The Spectrum of Engagement in HIV Care in the United States 
 
*Gardner E M et al. Clin Infect Dis. 2011;52:793-8003 
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Figure 2.2: Progression of HIV Infection, by CD4 Count and HIV RNA Viral Load 
 
*Pantaleo, NEJM, 1993.28 
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Table 2.1: Comparison of HIV Testing Strategies 
Testing Strategies Description 
Diagnostic Testing Selection or intended selection of patients because of clinical signs and 
symptoms suspected to be due to HIV infection 
Targeted Screening Selection or intended selection of all patients from among a defined 
subpopulation that are thought to have an increased likelihood of infection 
when compared with the base population 
Nontargeted 
Screening 
Selection or intended selection of any patient within the available population 
without respect to risk, but not intended to comprehensively include every 
available patient 
Universal Screening Selection or intended selection of all patients in the available population on a 
nontargeted basis; intended to comprehensively include every available patient 
*Adapted from Lyons, et al. Acad Emerg Med. 2009 26 
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Figure 2.3: Adults and Adolescents Living with a Diagnosis of HIV Infection, Year-End 
2008, 40 States and 5 US Dependent Areas 
 
*CDC, HIV Surveillance Report, vol. 21. 200991 
  
   
CHAPTER 3: RESEARCH DESIGN AND METHODS 
 
Study Design: A Before-After Intervention Analysis 
This study used a before-after intervention analysis design to assess a) HIV testing, 
b) the detection of new HIV-infected persons, and c) the risk of progression to AIDS among 
newly-diagnosed persons, before and after the implementation of a routine, opt-out HIV 
testing program in North Carolina STD clinics. The impact of the intervention was 
determined by comparing the outcome frequencies before and after the implementation of 
the program (before: July 1, 2005 – October 31, 2007; after: November 1, 2007 – June 30, 
2011). Data from 28 months prior to the implementation of the intervention was used as a 
comparison group. 
To examine the success of this routine, opt-out HIV testing program, we compared 
post-implementation data from STD clinics with pre-implementation data from the same STD 
clinics.  A cluster randomized trial would be the ideal study design to isolate the effects of 
the intervention. However, the intervention was not randomized to clinical sites at the start of 
program implementation. Randomization cannot occur after the introduction of the 
intervention, so an observational retrospective study design must be used. 
All North Carolina STD clinics participated in this routine, opt-out HIV testing 
intervention. A before-after design with an internal comparison group represented the best 
approximation of a counterfactual. By comparing HIV testing and diagnoses before and after 
the implementation of the intervention within the same facilities, we hoped to isolate the 
effect of the intervention without many other pre- and post-intervention differences. 
However, not all STD clinics were identical to one another. To account for underlying 
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differences between STD clinics, we used multilevel regression models with county-specific 
random intercept terms. 
Our before-after design was further strengthened by the large number of HIV tests 
performed in the STD clinics (over 400,000) and the large number of STD clinics in the state 
(102). This large sample size allowed us to stratify our results by patient and clinic 
covariates to evaluate if the impact of the intervention was uniform across all population 
subgroups. HIV testing protocols and technologies did not change over the study period; the 
only change to testing practices was the introduction of the intervention in November 2007. 
North Carolina is a geographically and demographically-diverse state, which will make our 
results generalizable to STD clinic patients in the Southeastern region. 
This before-after study design avoided issues of confounding that would have biased 
our results if STD clinics were compared to other types of facilities, such as private physician 
offices. However, by restricting our analysis to STD clinics, we limited the generalizability of 
our results to the STD clinic patient population. 
 
Study Setting: North Carolina STD Clinics 
The Southeastern United States bears a disproportionate burden of HIV infection, 
accounting for nearly 50% of the new AIDS cases in the United States in 2009 and 2010.14,40 
The rate of new HIV infections (23.8 per 100,000) and new AIDS diagnoses (11.6 per 
100,000) in North Carolina is higher than the national average (HIV: 21.1 per 100,000; 
AIDS: 11.2 per 100,000).40 Due to demonstrated need for HIV prevention activities in North 
Carolina, the state was chosen as a grantee for the CDC’s expanded HIV testing initiative in 
2007.2 
In North Carolina, the expanded HIV testing program focused on initiating or 
expanding HIV testing in the following venues: STD clinics, county jails, prisons, emergency 
departments, and community health centers.40 In late 2007, North Carolina modified its 
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administrative code to allow clinical facilities to remove the requirement for a separate 
written consent form for HIV and to incorporate routine, opt-out HIV testing.92 This policy 
change led to the establishment of many new HIV testing programs with routine, opt-out 
testing protocols. 
With this intervention, a conventional, non-rapid, blood-based HIV test was offered to 
every STD clinic patient. Blood samples were tested at the State Laboratory for Public 
Health (SLPH), with automatic pooling for detection of acute HIV infection by ribonucleic 
acid (RNA) testing.  Before the implementation of the intervention, HIV testing was 
performed selectively based on risk and presumptive syphilis status using an opt-in protocol 
with separate written consent. A standardized protocol for routine, opt-out HIV testing was 
used by all STD clinics that participated in the intervention (n=102).   
 
Data Sources 
Subject inclusion in this analysis was conditional on the successful completion of an 
HIV test.  Therefore, HIV testing data was used as the primary data source. Multiple data 
sources provided a comprehensive picture of HIV testing in North Carolina STD clinics 
(Table 3.1). 
 
STD Clinic Data and Laboratory Data 
Data on demographic information and HIV testing results were abstracted from the 
SLPH electronic laboratory database. A paper form containing patient demographic and 
clinical information was filled out by STD clinic staff upon HIV testing, and accompanied 
each blood sample sent to and processed at the SLPH.  
Once the blood sample arrived at the SLPH, the demographic and clinical 
information from this form was entered into the SLPH electronic database. Laboratory test 
results were added to the patient’s SLPH record. The SLPH electronic database is regularly 
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maintained by staff members of the North Carolina Division of Public Health based in 
Raleigh, NC. 
 
Data for HIV-Infected Persons 
All persons who tested positive for HIV on both a 3rd generation EIA laboratory test 
and a confirmatory Western Blot laboratory test were considered confirmed HIV-infected 
cases by North Carolina (Figure 3.1).40 Persons who tested negative on the 3rd generation 
EIA laboratory test but tested RNA-positive for HIV viral RNA were designated as acute HIV 
infections, and were also considered confirmed HIV-infected cases.  
All HIV-positive test results from the SLPH database were linked to or entered into 
the electronic HIV/AIDS Reporting System (eHARS). eHARS is the surveillance system 
used by the North Carolina Division of Public Health to collect and organize information on 
all HIV-infected cases in North Carolina. eHARS data are collected from state-mandated 
HIV case report forms and laboratory data, and updated by reports from HIV clinical 
providers. Other clinical data, such as the date of AIDS diagnosis, are also included in 
eHARS. 
If the HIV-positive test in the study period was the case’s first HIV-positive test result 
in North Carolina, a new eHARS record was created for that patient and the patient was 
considered a new HIV diagnosis for surveillance purposes. If, however, the same patient 
was previously entered in eHARS, their positive test result during the study was 
documented in the patient’s pre-existing eHARS record and the patient was considered a 
previous HIV diagnosis for surveillance purposes. Protocol dictates that disease intervention 
specialists interview new HIV-infected cases, perform tracing of sexual contacts, and help 
bridge new HIV-infected cases to HIV-specific medical care. 
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Clinic-Level Covariates 
Clinic-level covariate data was obtained from publically-available datasets, including 
data from the US Census Bureau (metro/micropolitan statistical area categorizations, county 
population density, percentage living below poverty line), clinic-specific information 
(presence of an in-house HIV clinic), and published North Carolina HIV/AIDS surveillance 
reports (reported HIV case rate for the STD clinic county). 
 
Aim 1: HIV Testing and Case Detection 
Estimate the impact a routine, opt-out expanded HIV testing intervention on HIV testing 
patterns and the detection of new HIV-infected cases in North Carolina STD clinics 
 
Study Population 
The study population included all patients tested for HIV in North Carolina STD 
clinics in the 28 months prior to the implementation of the intervention through June 30, 
2011 (pre-intervention period: July 1, 2005 – October 31, 2007; post-intervention period: 
November 1, 2007 – June 30, 2011). Included patients were aged 18-64 and maintained a 
permanent residence in North Carolina.  
STD clinic resources and programs were not restricted to residents of North 
Carolina. However, any out-of-state patients who tested HIV-positive were not included in 
the North Carolina surveillance database. For these out-of-state cases, the confirmation of 
their HIV-infected status, designation as a new or previously known infected case, and 
clinical measures (e.g. CD4 counts, viral loads, concurrent AIDS diagnoses) would not be 
available. Therefore, out-of-state individuals were excluded from analysis. 
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Outcome 
Outcome 1: HIV Testing 
The first outcome for Aim 1 was HIV testing performed in the STD clinics, evaluated 
both as the absolute number of HIV tests per month and as the HIV testing rate per 100,000 
population. All persons included in the study population were tested for HIV and contributed 
to this outcome. The absolute number of HIV tests was evaluated over time with serial 
monthly cross-sections evaluated using interrupted time series analysis. The HIV testing 
rate per 100,000 population was evaluated in both interrupted time series analysis and 
multilevel regression modeling. 
Annual intercensal population estimates were used as the denominator for the HIV 
testing rate (Table A2.7). Due to limitations of the available datasets, we could not create a 
denominator-based on the actual number of patient visits in the STD clinics. Intercensal 
population estimates are annually-updated population estimates using data from the most 
recent national census to capture population changes between 10-year census surveys, 
stratified by county and by demographic subgroups. 
 
Outcome 2: Newly-Diagnosed HIV-Infected Persons 
The second outcome for Aim 1 was the identification of newly-diagnosed HIV-
infected persons in North Carolina STD clinics. This outcome was evaluated both as the 
absolute number of newly-diagnosed HIV-infected persons and as the HIV positivity per 
1,000 HIV tests. An HIV-infected diagnosis was defined as a person who tested HIV positive 
on a 3rd generation blood-based enzyme immunoassay (EIA) diagnostic test and was 
confirmed positive via Western Blot, or a person who tested HIV negative on a 3rd 
generation blood-based EIA diagnostic test, but positive on HIV RNA testing (Figure 3.1).93  
All HIV-infected cases reported to the North Carolina Division of Public Health were 
categorized as new or previously-known, based on surveillance records.  Previously-known 
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patients had either already been reported to North Carolina Division of Public Health, or 
were known to be a confirmed case of HIV in another state. All preliminary HIV test results 
(rapid tests, EIAs, etc.) were confirmed by Western Blot analysis, in accordance with North 
Carolina testing protocols. 
For this study, a new HIV-infected case met the above diagnostic criteria for a 
confirmed HIV-infected case, but had never before been reported as a case of HIV. A new 
HIV-infected case was defined as a person with a positive HIV test result in the same 
calendar month as the patient’s HIV diagnosis date as documented in eHARS. This window 
period allowed for potential reporting delays and uncertainty regarding some persons who 
lacked a specific date of HIV diagnosis; these persons were assigned to the 15th day of their 
diagnosis month. This approximation recoded 69 HIV-infected cases as newly-diagnosed, 
when they otherwise would have been considered a previous diagnosis (3.3% of patients 
with a positive test result, 0.009% of the total study population). 
All results were stratified by patient and clinic characteristics to identify trends in 
population subgroups and assist with public health decision making. These stratified results 
will help to direct limited public health resources to areas of greatest impact, as well as 
identify areas of continued need. 
 
Exposure 
The exposure variable in this analysis was time, which was used to denote the 
presence or absence of the intervention in the STD clinic. The intervention was introduced 
to STD clinics in November 2007.  Exposure was coded dichotomously for descriptive 
analyses; persons tested for HIV on or after November 1, 2007 were considered “exposed” 
and those tested prior to that date were considered “unexposed”. A monthly time scale was 
used to examine temporal trends.  
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Base case regression models included a lag period of 3 months. The inclusion of a 
lag period allowed for the exclusion of a short period of unusual variability post-intervention 
that may not be attributable to the intervention under study. Lag periods capture the real-
world challenges of implementing an intervention in a clinical setting, while allowing staff and 
clinicians to fully adjust to and operationalize the intervention as dictated in standard 
operating procedures. Previous studies of HIV testing programs in North Carolina 
community health centers indicate that some HIV testing outcomes may be inflated during 
this lag period, before the outcomes stabilizes.94 Therefore, in base case regression 
analyses, persons tested prior to November 1, 2007 were considered “unexposed” and 
those tested after February 1, 2008 were considered “exposed”; HIV testing and case 
detection patterns for persons in the lag period were modeled separately. In sensitivity 
analyses, the length of the lag period was varied from 0 months (no lag) to 6 months.   
 
Patient and Clinic Covariates 
As our analysis used a quasi-experimental before-after study design within a closed 
set of STD clinics, the primary difference between pre- and post-intervention periods should 
only have been the introduction of the intervention. This approach is complementary to a 
randomized controlled trial, in which the investigators aim to create two identical groups that 
only differ by the assignment of exposure. Covariates that may have been associated with 
the outcome were determined a priori, and included in statistical modeling. Since the 
exposure variable was time and the intervention was a direct result of an external public 
health initiative, we did not expect a confounding relationship between covariates and the 
exposure. Models were adjusted for sets patient covariates (gender, race/ethnicity, age), 
clinic covariates (metropolitan status, population density, percentage of county living below 
the poverty line, presence of an in-house HIV clinic, baseline HIV case rate), or all 
covariates. Adjusted effect estimates were compared with crude, unadjusted effect 
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estimates. Due to our quasi-experimental study design, we anticipated that the crude, 
unadjusted effect estimates would be valid. 
Patient date of birth was used to calculate age at time of HIV testing and was coded 
categorically (age 18-24, 25-34, 35-44, 45-64). Sex was assessed as male/female. Patient 
race/ethnicity was categorized as non-Hispanic white, non-Hispanic black, Hispanic, or other 
(Asian, Hawaiian/Pacific Islander, Native American, multi-race).  
Urban/rural categorizations of counties were described by the US Census Bureau’s 
metropolitan/micropolitan statistical area groups (MeSA, MiSA, neither) and by the county 
population density (<199, 200-399, 400-599, ≥600 persons per square mile).95,96 The 
percentage of the county’s population living below the poverty line was used as a marker of 
the economic status of each county (<15%, 15-19.9%, 20-24.9%, ≥25%).97 The average 
baseline county-level estimated HIV case rate per 100,000 from 2005 to 2007 was included 
as a categorical variable categorized for analysis as (0-4.9, 5-9.9, 10-14.9, ≥15).40 A 
dichotomous variable identified the presence or absence of an in-house HIV clinic; STD 
clinics with an in-house HIV clinic were Durham, Mecklenberg, and Wake Counties. 
 
Data Analysis 
Preliminary Descriptive, Univariate, and Bivariate Analyses  
The temporal trends of HIV testing and case detection were first assessed 
descriptively. The frequency and distributions of all variables (exposure, outcomes, and 
covariates) were assessed using tabular and graphical representations. Bivariate 
associations of potential covariates by exposure level (pre/post intervention) were also 
presented descriptively using counts and frequency distributions. Chi-square statistics were 
calculated to describe differences in covariate distributions by exposure level. 
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Assessing Missing Data 
The amount of missing exposure or outcome data in this analysis was unknown. 
SLPH and eHARS surveillance databases may have had incomplete records. We assumed 
that only a small amount of the exposure or outcome data were missing. Unfortunately, this 
assumption could not be verified.  
The covariates were evaluated for patterns of missingness in frequency tables, both 
overall, and in strata of the exposure (pre- and post-intervention). Given the small proportion 
of study subjects missing individual-level covariate information (age, sex, race/ethnicity; 
n=9,961, 2.4% of patients with a valid HIV test result), a complete case analysis was 
conducted. The final analysis cohort included 402,774 unique HIV tests performed over 72 
monthly time points. 
 
Multivariate Analyses 
Multivariate analyses were conducted using two distinct, but complementary 
methods: interrupted time-series analysis and multilevel modeling. Both methods 
incorporate time, however, under different functional assumptions. Interrupted time-series 
analysis uses monthly cross-sections as the unit of analysis and controls for underlying 
temporal trends to examine changes in the outcome over time. Multilevel models evaluate 
the overall impact of the intervention while controlling for clinic-level correlation.  
 
Time Series (ARIMA) Models: Rationale 
Interrupted time series analyses evaluate non-randomized interventions by 
assessing a repeated series of observations on the same study population.98,99 These 
analyses evaluate the modeled exposure-outcome associations over time, in the context of 
underlying temporal trends. The unit of analysis for interrupted time series analyses is the 
cross-sectional time period (months, in this analysis). 
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Interrupted time series analysis is considered the most rigorous evaluation method 
for non-randomized observation studies.100 Although initially designed for use in economics, 
interrupted time series analyses are now used regularly in evaluations of community 
interventions, new clinical policies, and medication use.98,101,102 
 
Time Series (ARIMA) Model: Design 
Interrupted time series analyses were used to determine if the change in HIV testing 
or case detection after implementation of the intervention was greater or less than would be 
expected in the absence of the intervention, while accounting for time-based correlation in 
the data.98,99 Segmented regression lines characterized the temporal trends in the outcome 
by the ‘level’ at which the segment starts (intercept) and the trend (slope). The analysis 
examined how the level (intercept) and trend (slope) of the segment changed after the 
introduction of the intervention. A lag period, or transitional period, of 3 months was 
specified to account for a period of program ramp-up to ideal levels. In sensitivity analysis, 
the lag period was varied from 0 months (no lag) to 6 months. 
The specific interrupted time series technique used in this analysis was 
autoregressive integrative moving average (ARIMA) models. ARIMA models are used when 
error terms are potentially associated with one another and not independent.98,99,103 Since 
this analysis used repeated sampling of the same STD clinics over time, we expected that 
error terms would be correlated with one another. Based on autocorrelation and partial 
autocorrelation plots, we observed an autocorrelation of 1 (AR=1) for all outcomes except 
HIV positivity. Autocorrelation of 1 means that the outcome at time 2 is correlated with the 
outcome at time 1, the outcome at time 3 is correlated with the outcome at time 2, etc.99 
The ARIMA model was fit to a binomial distribution with an identity link to calculate 
mean differences (MDs) and corresponding 95% confidence intervals. Potential covariates 
were considered for inclusion in the model according to the a priori criteria described above. 
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Base ARIMA Model:98 
𝑌𝑡 = 𝛽0 + 𝛽1 ∗ 𝑡𝑖𝑚𝑒𝑡 + 𝛽2 ∗ 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛𝑡 + 𝛽3 ∗ 𝑡𝑖𝑚𝑒 𝑎𝑓𝑡𝑒𝑟 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛𝑡 + 𝑒𝑡 
𝑌𝑡: mean outcome in month t 
Time: time in months at time t from the start of the study period 
Intervention: indicator for time t occurring before (intervention = 0) or after (intervention = 1) 
the implementation of the intervention 
Time after intervention: continuous variable counting number of months after intervention at 
time t, coded 0 before the intervention 
𝛽0: pre-intervention intercept 
𝛽1: pre-intervention slope, change in the outcome  per month before the intervention 
𝛽2: post-intervention intercept, immediate change after introduction of intervention 
𝛽3: post-intervention slope attributable to the intervention, incremental difference in slope 
compared with the pre-intervention slope 
𝑒𝑡: error term, random variability not explained by the model 
 
Time Series (ARIMA): Outcome 
The primary outcome of interest in the ARIMA model was the change in outcome 
(HIV testing or case detection) attributable to the intervention (𝛽3). The overall post-
intervention slope was described as the sum of the pre-intervention slope (𝛽1) and the 
change in outcome attributable to the intervention (𝛽3). 
In addition to identifying the overall impact of the intervention, the ARIMA models 
were stratified by patient- and clinic-level covariates. Due to the ecologic structure of the 
ARIMA model, a separate dataset of each population subgroup was created and then 
analyzed using ARIMA regression models. 
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Multilevel Models: Rationale 
We used multilevel, or hierarchical, regression models to account for correlation 
between STD clinics. Persons who visited a specific STD clinic may be similar to one 
another, yet different from patients at other STD clinics. This clustering of similar patients 
within STD clinics violates the independence assumption of traditional linear models.104,105 
Advanced modeling techniques that account for the correlation between STD clinics were 
necessary to calculate valid estimates.  
Multilevel models included both individual-level and group-level covariates. In this 
analysis, patients were nested within STD clinics, and the exposure-outcome association 
may have been influenced by both patient-level and clinic-level covariates. Multilevel models 
provide an intermediate approach between analyzing all patients as an aggregate 
population (ignoring clinic-level covariates) and creating a separate regression line for each 
clinic, which may overestimate the differences between clinics.104,105  
 
Multilevel Models: Design 
Multilevel models are “mixed” models that can include both random and fixed effects. 
Random components can be introduced for either the intercept term, slope term, or both 
terms.  For our base case model, we fit a fixed-slope random intercept model with a 
separate intercept term for each county. The random intercept term allowed for each STD 
clinic to have its own intercept, but assumed that the intervention had the same effect in all 
STD clinics. The degree of correlation within and between STD clinics was quantified using 
the intraclass correlation coefficient (ICC).   
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Fixed-Slope Random intercept model:104,105 
𝑦𝑖𝑗 = (𝛽1 + 𝜁1𝑗) + 𝛽2𝑥𝑖𝑗 + ⋯ + 𝛽𝑝𝑥𝑝𝑖𝑗 + 𝜖𝑖𝑗 
i: patient-specific indicator 
j: facility-specific indicator 
𝛽1: patient-specific fixed intercept 
𝜁1𝑗: facility-specific random intercept, deviation of facility j’s intercept from the mean intercept 
𝛽1; weighted average of the within-facility and between group-facility intercept estimates; 
normally distributed with mean=0 and variance=ψ [~N(0,ψ)] 
𝛽2: patient-specific fixed slope 
𝛽𝑝: coefficient for additional covariates 
𝜖𝑖𝑗: patient-specific error; random deviation of 𝑦𝑖𝑗 from facility j’s mean 
 
In sensitivity analyses, this random intercept model was compared with a model 
without random components (fixed effects model). Fixed effects models assume that no 
parameters vary by group (or clinic, in this case) – including both intercept and slope 
parameters. These models essentially examine the study population as one aggregate 
group, ignoring possible correlation between clinics. 
 
Multilevel Models: Intervention/Time 
Time, the exposure variable, was coded as a 3-level categorical variable in the base 
case scenario to allow for the 3-month lag period. A knot was placed at the start of the lag 
period (November 1, 2007) and another at the start of the intervention analysis period used 
in analysis (February 1, 2008).  
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Sensitivity analyses considered two alternative lag periods of 0 months (no lag) and 
6 months. In the sensitivity analysis that did not include a lag period, time was coded 
dichotomously with the only knot on November 1, 2007. The 6-month lag period was 
modeled similarly to the 3-month lag, but with the second knot occurring at May 1, 2008. 
To account for additional underlying temporal trends, models were adjusted for the 
year of HIV testing using an indicator term. All models were calculated with and without this 
calendar year indicator variable. 
 
Multilevel Models: Outcomes 
The HIV testing rate per 100,000 population was modeled using a Poisson 
distribution and a log link. Poisson regression, which can either examine counts or rates, 
needs an offset term when the outcome is in the form of a rate. The offset for this analysis 
was calculated as the log of the intercensal population denominator. These Poisson models 
yielded rate ratios (RR) and corresponding 95% confidence intervals. Because we lacked 
individual-level denominator data, we only considered an unadjusted, fixed effects 
regression model. 
HIV positivity is a rare outcome; the overall HIV positivity from the CDC-funded HIV 
testing initiative in North Carolina in 2010 was 0.25% (includes all emergency departments, 
community health centers, STD clinics, and county jails).40 This analysis examined serial 
cross-sections and could not evaluate risk of HIV acquisition over time. A model with a 
binomial distribution and logit link function was used to calculate odds ratios (ORs), which 
approximated prevalence ratios, and corresponding 95% confidence intervals. 
Multilevel models result in an overall estimate of association, not clinic-specific 
estimates. The overall beta coefficient for the exposure represented the expected change in 
the log HIV positivity with the implementation of the intervention in all STD clinics in North 
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Carolina. The width of the confidence intervals was influenced by degree of variability 
observed at the facility level. 
 
Multilevel Models: Covariates 
As discussed above, our results should not be biased by confounders because we 
used the STD clinics as internal controls. However, as our comparator group is not a perfect 
counterfactual, covariates determined a priori to influence the outcome were evaluated as 
potential confounders.  Models were adjusted for sets of covariates: patient-level covariates 
(gender, race/ethnicity, age), clinic-level covariates (metropolitan status, population density, 
percentage of the county below the poverty line, presence of an in-house HIV clinic, and 
baseline HIV case rate), and patient + clinic level covariates. Nested models were compared 
to one another using likelihood ratio tests at an a priori significance level of 0.10. 
All statistical analyses will be conducted with SAS version 9.2 (SAS Institute, Cary, 
NC).106 
 
Aim 2: Progression to AIDS 
Estimate the impact of a routine, opt-out expanded HIV testing program on the risk of 
progression to AIDS within 12 months of initial HIV diagnosis among newly-identified HIV-
infected cases detected in North Carolina STD clinics 
 
Study Population 
The study population consisted of all patients newly diagnosed as HIV-infected in 
North Carolina STD clinics from 28 months prior to intervention implementation (July 1, 
2005) through June 30, 2011.  The inclusion criteria were identical to the outcome definition 
for a new HIV-infected case in Aim 1. 
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Outcome 
Outcome: Risk of Progression to AIDS 
The outcome for Aim 2 was the risk of progression to AIDS after a new diagnosis of 
HIV, defined as the proportion of newly diagnosed HIV-infected patients who progress to 
AIDS (and were reported as such) within 1 year of their initial HIV diagnosis. AIDS cases 
were based on the North Carolina Division of Public Health definition of a person who meets 
certain immunologic criteria (CD4 count <200 or <14%) or who becomes ill with one of 26 
AIDS-defining conditions.40 
Sensitivity analyses varied the window period for progression to AIDS from 1 month 
to 18 months. Specific alternative outcome time frames considered were 1 month, 6 months, 
and 18 months post-diagnosis. Although the CDC uses a 12 month window period to define 
“late HIV diagnosis”, the North Carolina Division of Public Health uses a 6 month time 
frame.15,40 Other definitions of “late HIV diagnosis” from the literature include AIDS at 
diagnosis, based on the CD4 count measured within 1 or 3 months post-diagnosis.107-109 To 
allow for potential reporting delays or imprecise dates of HIV or AIDS diagnosis, an 
additional 15 days were added to each outcome time period (1 month + 15 days, 6 months + 
15 days, etc.).  
 
Exposure 
As in Aim 1, the exposure for this analysis was time, which was used to denote the 
presence or absence of the intervention in the STD clinic. Patients diagnosed post-
intervention (after November 2007) were categorized as “exposed”; those diagnosed pre-
intervention were categorized as “unexposed”.   
In Aim 1, we included a lag period of 3 months, to allow for greater variability 
immediately post-intervention. Evidence does not suggest a similar short-term increase in 
variability in the outcome of Aim 2. Therefore, no lag period was included in this aim. This 
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assumption was evaluated in sensitivity analysis with the inclusion of 3 and 6 month lag 
periods. 
 
Patient and Clinic Covariates 
As described in Aim 1, covariates were considered for adjustment if they were 
determined, a priori, to be associated with the outcome of interest. In addition to the 
covariates examined in Aim 1, we also considered the patient’s self-reported previous HIV 
testing history (yes/no) and self-reported risk profile. A combination variable that included 
gender and self-reported sexual risk factors was created, yielding the following categories: 
female, male heterosexual, and man who had sex with other men (MSM). These risk groups 
were selected for this variable based on the key risk groups in North Carolina.40 We 
expected the unadjusted, crude effect estimate to be the most valid, but tested sets of 
covariates for model inclusion (patient covariates [gender, race/ethnicity, age, previous HIV 
test, risk behaviors], clinic covariates [metropolitan status, population density, percentage of 
the county living below the poverty line, presence of an in-house HIV clinic, baseline HIV 
case rate], patient and clinic covariates) using likelihood ratio tests in nested models with an 
a priori significance level of 0.10. 
 
Data Analysis 
Preliminary Descriptive, Univariate, and Bivariate Analyses 
Descriptive and graphical analyses of progression to AIDS within 1, 6, 12, and 18 
months provided an overview of all HIV-infected cases. As described in Aim 1, the 
frequency and distributions of all variables (exposure, outcome, and covariates) were 
assessed using tabular and graphical representations. Bivariate associations of potential 
covariates by exposure level (pre- or post-intervention) were also presented descriptively 
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using counts and frequency distributions. Chi-square statistics were calculated to describe 
differences in covariate distributions by exposure level. 
 
Assessing Missing Data 
As noted in Aim 1, missing data may be present in set of covariates. Given the small 
proportion of study subjects missing individual-level covariate information (age, sex, 
race/ethnicity, previous HIV test, risk group; n=39, 3.1% of patients with a new HIV 
diagnosis), a complete case analysis was conducted. The final analysis cohort included 
1203 persons newly diagnosed with HIV during the study period. 
 
Multilevel Models: Rationale and Design 
As described in the analysis plan for Aim 1, the patients in this dataset were naturally 
clustered within STD clinics, which introduces a correlation structure that violates the 
independence assumption of traditional generalized linear models.104,105 The correlation that 
exists within and between STD clinics was accounted for with multilevel modeling. The 
structure of the multilevel models used in this aim mirrored those described in the Aim 1 
analysis plan with a county-specific random-intercept model as a base case model structure. 
Fixed effects models that lacked random effects components were explored in sensitivity 
analyses. 
 
Multilevel Models: Outcomes 
Based on national and local surveillance data, we estimated the proportion of 
persons who would progress to AIDS within 12 months of their initial HIV diagnosis be 
approximately 10-30%. As such, a binomial regression model was used to calculate risk 
ratios (RR).  The overall beta coefficient for the model represented the expected change in 
the log risk of progression to AIDS within a specific time period with the implementation of 
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the intervention in all STD clinics in North Carolina. Facility-specific beta coefficients were 
not evaluated.  
All results were stratified by patient and clinic characteristics to identify trends in 
specific population subgroups. Stratified estimates were obtained with interaction terms. The 
interaction terms were tested for significance using likelihood ratio tests at an a priori 
significance level of 0.10. 
All statistical analyses were conducted with SAS version 9.2 (SAS Institute, Cary, 
NC).106 
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Tables and Figures 
 
Table 3.1: Data Sources 
 
Data Source Variables 
NC State Laboratory of Public Health HIV test results 
Patient demographics (age, gender, race, risk 
factors for HIV acquisition, previous HIV testing 
history) 
 
Electronic HIV/AIDS Reporting System (eHARS) Distinguish new or previously-known positives 
Date of AIDS diagnosis 
 
US Census Bureau Metropolitan/Micropolitan Statistical Areas 
County population density 
Percentage of county living below poverty line 
 
North Carolina HIV/AIDS Surveillance Reports Estimated HIV/AIDS incidence in clinic region 
 
Facility-Specific Data Joint HIV/STD clinic 
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Figure 3.1: North Carolina State Lab of Public Health HIV Testing Algorithm 
 
   
CHAPTER 4: IMPACT OF A ROUTINE, OPT-OUT HIV TESTING PROGRAM ON HIV 
TESTING AND CASE DETECTION IN NORTH CAROLINA SEXUALLY-TRANSMITTED 
DISEASE CLINICS 
 
Introduction 
In the United States, approximately 20% of people infected with HIV are unaware of 
their HIV-infected status; disease transmission from these individuals accounts for 50% of 
new HIV infections.3,5 Effective HIV testing programs are essential to identify HIV-infected 
persons and enroll them in medical care, thereby slowing disease progression and reducing 
further HIV transmission.18,22 In 2006, the Centers for Disease Control and Prevention (CDC) 
recommended routine, opt-out HIV testing in clinical settings.1 From 2007 through 2010, 
testing programs funded by the CDC’s expanded HIV testing initiative performed 2.8 million 
HIV tests and identified over 18,000 new HIV-infected cases.2 However, these cases 
represent only a small fraction of the approximately 150,000 new HIV infections acquired 
over the same period.6 
Routine, opt-out HIV testing can be feasible to implement and acceptable to both 
patients and providers.7,9,10 Although the number of HIV tests performed increases with the 
introduction of an expanded HIV testing program, the impact on the identification of new 
HIV-infected cases has been inconclusive. While some expanded HIV testing programs 
showed an increase in case detection, others showed a decrease or no 
change.7,9,13,62,63,65,110-112 These programs have been limited by small numbers and a focus 
on clinical settings with minimal HIV testing prior to implementation. 
We conducted a statewide, before-after analysis of a routine, opt-out expanded HIV 
testing program in all 102 North Carolina sexually transmitted disease (STD) clinics. North 
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Carolina, like many southeastern states, bears a large burden of HIV infection and STDs.14 
The program’s impact was measured by the number of HIV tests performed and new 
detection of HIV-infected cases. We aimed to determine the incremental impact of an 
expanded HIV testing program in a clinical setting with a high baseline level of HIV testing. 
 
Methods 
Study Population & Setting 
This study included all patients aged 18-64 years who were tested for HIV in North 
Carolina’s 102 county-level STD clinics from July 1, 2005 through June 30, 2011. Non-North 
Carolina residents and patients lacking an HIV test result were excluded from analysis 
(n=1,149 of 414,015 HIV tests). 
Patients who agreed to HIV testing had blood samples drawn and, along with a form 
with patient demographic information, processed at the North Carolina State Laboratory for 
Public Health (SLPH). At the SLPH, the samples were tested for HIV antibodies using a 3rd 
generation enzyme immunoassay (EIA); all reactive samples were confirmed via Western 
Blot. EIA-negative samples were pooled for acute HIV testing by polymerase chain reaction 
for viral RNA. Test results and demographic information were entered into the SLPH HIV 
testing database; results were provided to the patient in a follow-up STD clinic visit. All 
patients with a positive HIV test were checked for a previous entry in the state HIV 
surveillance database, the electronic HIV/AIDS reporting system (eHARS). If no prior record 
existed, the patient was entered into eHARS as a new HIV-infected case. Patient-level data 
for this analysis were collected by linking the SLPH and eHARS electronic surveillance 
databases by a unique HIV testing identifier. 
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Intervention: Expanded HIV Testing Program 
The North Carolina Expanded HIV Testing Program was introduced in November 
2007, with a focus on routine, opt-out HIV testing in clinical settings. Because of the high-
risk patient population, HIV testing was already quite common in STD clinics.113 Therefore, 
unlike lower risk clinical populations, the expanded HIV testing program in STD clinics 
focused on providing routine screening to all STD clinic patients. 
 
Exposure Definition 
The intervention was implemented on November 1, 2007. We assumed a lag period 
of 3 months from the start date of the intervention to full implementation. Therefore, in 
regression analyses, persons tested for HIV prior to November 1, 2007 were considered 
“unexposed” to the expanded HIV testing program; persons tested for HIV after February 1, 
2008 were considered “exposed”. This lag period was varied from 0 to 6 months in 
sensitivity analyses (Table A2.6, Table A2.9). 
 
Outcome Assessment 
Two primary outcomes were evaluated: HIV testing and the new detection of HIV-
infected cases. HIV testing was measured as the number of HIV tests performed, as well as 
the HIV testing rate per 100,000 persons, based on annual intercensal population estimates 
(Table A2.7).114 Case detection was measured as both the number of new HIV-infected 
cases and HIV-positivity per 1000 HIV tests. 
A new case of HIV infection was defined as a patient with a positive HIV test in the 
same calendar month as the person’s diagnosis date in eHARS. This window period 
accounted for possible reporting delays and uncertainty regarding patients who lacked an 
exact date of HIV diagnosis; these patients were assigned to the 15th day of their diagnosis 
month. This approximation recoded 69 HIV-infected cases as newly-diagnosed, when they 
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otherwise would have been considered a previous diagnosis (3.3% of patients with a 
positive test result, 0.009% of the total study population). 
Patient demographics at the time of HIV testing were abstracted from the SLPH 
database and included gender (male, female), race/ethnicity (non-Hispanic white, non-
Hispanic black, Hispanic, other), and age. STD clinics were categorized by population 
density (<199, 200-399, 400-599, ≥600 persons per square mile), metropolitan/micropolitan 
statistical areas (MeSA, MiSA, neither), and proportion of the county living below the poverty 
line (<15%, 15-19.9%, 20-24.9%, ≥25%).95-97 A baseline HIV rate was calculated as he 
average number of reported HIV cases per 100,000 from 2005 through 2007 (categorized 
for analysis as 0-4.9, 5-9.9, 10-14.9, ≥15).115 A dichotomous variable identified the presence 
or absence of an in-house HIV clinic; STD clinics with an in-house HIV clinic were Durham, 
Mecklenberg, and Wake Counties. 
 
Statistical Analysis 
Descriptive analyses were used to examine trends in HIV testing and case detection 
before and after the introduction of the intervention. Multivariate regression analyses were 
conducted with two distinct approaches: interrupted time series analyses and multilevel 
modeling. Given the small proportion of study subjects missing individual-level covariate 
information (age, sex, race/ethnicity; n=9961, 2.4% of patients with a valid HIV test result), a 
complete case analysis was conducted. The final analysis cohort included 402,774 unique 
HIV tests performed over 72 monthly time points. 
Interrupted time series methods, specifically autoregressive integrated moving 
average (ARIMA) models, were applied to serial monthly cross-sections of HIV testing data. 
Because HIV testing in one month is dependent on testing in the prior month and influences 
testing in subsequent months, we used ARIMA models to account for underlying temporal 
correlation between parameter estimates and their residual errors. This method describes 
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the trend (slope) of an outcome over time, and how this trend changes with the introduction 
of an intervention. We identified parameters representing the (a) pre-intervention intercept, 
(b) pre-intervention slope, (c) overall post-intervention slope, and (d) change in slope 
attributable to the intervention. Mean differences (MDs) and corresponding 95% confidence 
intervals (95% CIs) were calculated for all patients and stratified by patient- and clinic-level 
characteristics. 
To evaluate the overall association between the intervention and the rate of HIV 
testing per 100,000 population, we used Poisson regression to calculate rate ratios and 95% 
CIs. The rate denominator was created from annual intercensal population estimates. To 
broadly adjust for time trends, models were also adjusted for calendar year. 
Fixed slope random intercept multilevel regression models were used to evaluate the 
intervention’s impact on HIV case detection, while accounting for clustering by STD clinic. 
Intercepts were allowed to vary to accommodate different county-level HIV risk levels. In 
sensitivity analyses, we compared the random-intercept models to models without county -
level clustering (Table A2.8). Since HIV-positivity is a rare outcome, we used logistic 
regression to calculate odds ratios (ORs), corresponding 95% CIs, and confidence limit 
ratios. 
With an externally-determined time point as the demarcation between the exposed 
and unexposed periods, measured covariates were not associated with the “exposure” 
(intervention) and could not be confounders. To address potential differences in the 
covariate distributions over time, the multilevel model was adjusted for patient- and clinic-
level characteristics (Table 4.1). An indicator for calendar year was added to broadly 
account for underlying time trends.  
All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC).106 
This study was approved by the Institutional Review Board of the University of North 
Carolina at Chapel Hill.  
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Results 
Patient Demographics 
Pre-intervention, 128,029 HIV tests were performed, of which 426 (0.33%) were new 
HIV-infected cases. In the post-intervention period, 274,745 HIV tests were performed, 
detecting 816 (0.30%) new HIV-infected cases (Table 4.1). 
Just over half of the tested patients were female, although more female patients 
were tested in the post-intervention phase (51.8% vs. 54.9%). The proportion of non-
Hispanic black patients increased from 53.18% to 58.40%, while the proportion of non-
Hispanic white, Hispanic, and other race/ethnicity decreased. The age distribution of 
patients receiving an HIV test did not change over the study period. Few changes in clinic-
level characteristics were observed between the pre- and post-intervention periods.  
 
Number of HIV Tests Performed 
In July 2005, the baseline number of HIV tests performed per month was 3832. Prior 
to the intervention, the number of HIV tests performed per month increased at a rate of 55 
tests per month (95% CI: 41, 72), or an increase of 0.81 tests per 100,000 persons per 
month (Figure 4.1; Table A2.2, Table A2.3). Post-intervention, the monthly increase in the 
number of tests slowed to 34 tests per month (95% CI: 26, 42), or an increase of 0.46 tests 
per 100,000 persons per month. Compared with the monthly rate of HIV testing predicted in 
the absence of the intervention, the monthly rate of HIV testing attributable to the 
intervention decreased by 20 tests per month (95% CI: -37, -5) or -0.35 tests per 100,000 
persons per month. 
This overall trend in HIV testing was driven by specific demographic subpopulations 
(Table 4.2; Table A2.2, Table A2.3). Decreases in the rate of HIV testing per 100,000 
population per month attributable to the intervention were observed among males (MD=-
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0.45, 95% CI: -0.70, -0.21), non-Hispanic blacks (MD=-1.57, 95% CI: -2.34, -0.80), 
Hispanics (MD=-1.55, 95% CI: -2.19, -0.92), and patients in the youngest age categories 
(18-24 years; MD=-1.34, 95% CI: -2.07, -0.61; 25-34 years: MD=-0.54, 95% CI: -1.03, -
0.05). Decreases in the rate of HIV testing per month attributable to the intervention were 
also pronounced in clinics located in counties of high population density (MD=-0.63, 95% CI: 
-1.0, -0.25) and high baseline HIV case rates (MD=-0.74, 95% CI: -1.1, -0.40).  
Unadjusted Poisson models identified an increase in the rate of HIV testing 
associated with the intervention (rate ratio=1.33; 95% CI: 1.32, 1.34). However, after 
adjustment for calendar year, the association was inverted (rate ratio=0.88; 95% CI: 0.85, 
0.91) and in agreement with the interrupted time series results, which showed a slight 
negative association. 
 
New HIV-Infected Cases 
The baseline number of new HIV-infected cases detected was 13.82 per month (95% 
CI: 10.82, 16.82), or 3.59 cases per 1,000 HIV tests per month (95% CI: 3.05, 4.12; Figure 
4.1, Table A2.4, Table A2.5). Little temporal trend in HIV-positivity per 1000 tests per month 
was observed in either the pre- or post-intervention time periods (pre-intervention MD=-0.02; 
95% CI: -0.05, 0.02; post-intervention MD=0.00, 95% CI: -0.02, 0.02). 
Despite the lack of a significant trend in HIV-positivity, the expanded HIV testing 
program did slightly mitigate the negative slope observed prior to the intervention (MD=0.01, 
95% CI: -0.02, 0.05; Table 4.3, Table A2.4, Table A2.5). This mitigation was driven by 
increases in monthly case detection rates attributable to the intervention among females 
(MD=0.03, 95% CI: 0.01, 0.07) and non-Hispanic black patients (MD=0.05, 95% CI: 0.00, 
0.10). Slight increases in the rate of case detection per month attributable to the intervention 
were also observed in clinics without an in-house HIV clinic (MD=0.03, 95% CI: -0.02, 0.07), 
and in counties with moderate levels of poverty and high baseline rates of HIV.   
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Based on the unadjusted multilevel regression model, the introduction of the 
expanded HIV testing program was associated with a 0.11% reduction in HIV-positivity 
(OR=0.89, 95% CI: 0.79, 1.00; Table 4.4). The inclusion of patient-level covariates slightly 
attenuated this association, but did not alter precision (OR=0.93, 95% CI: 0.82, 1.05). 
Adjustment of the multilevel model for calendar year attenuated the observed association 
completely to the null (OR=1.02, 95% CI: 0.69, 1.52) and adversely effected precision.  
 
Discussion 
Despite the CDC’s recommendation for routine, opt-out HIV testing in clinical 
settings, the impact of expanded HIV testing programs is unclear.1,7,9,13,62,63,65,110-112 We 
evaluated HIV testing and case detection of a routine, opt-out HIV testing program in North 
Carolina STD clinics using a before-after intervention analysis. Due to a consistent increase 
in HIV testing prior to the intervention, the incremental impact of the expanded HIV testing 
program was minimal.  
In the post-intervention phase, the monthly rate of HIV testing increased, but at a 
slower rate than before the intervention. This attenuation was driven primarily by a slower 
increase in the rate of HIV testing among patients regularly targeted for testing (males, non-
Hispanic blacks, Hispanics, younger patients) and increased testing rate attributable to the 
intervention in populations not traditionally considered at high-risk for HIV (females, non-
Hispanic whites).6,116  
Although the change in HIV testing rates attributable to the intervention among 
traditionally high-risk patients decreased, the overall rate of HIV testing per month continued 
to increase. HIV testing is an outcome bounded by the size and capacity of the STD clinic 
and cannot increase infinitely. By expanding HIV testing services, we believe that the 
intervention will eventually allow for a higher maximum level of HIV testing to be reached 
than would have been observed without the intervention. 
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Among Hispanics, the overall post-intervention rate of HIV testing decreased. This 
result is concerning: in the Hispanic community, HIV prevalence is high and many barriers 
complicate HIV prevention.40,117 However, underlying changes in the migrant Hispanic 
population due to poor employment in the economic downturn in 2008, which coincided with 
the post-intervention period, could explain this result. If the overall population of migrant 
Latino workers decreased, they would be removed disproportionately from the numerator of 
STD clinic clients but not from the intercensal population-based denominator, which could 
artificially decrease HIV testing rates. 
Since the greatest increase in HIV testing was among persons at lower risk for HIV 
acquisition, the incremental increases in case detection were minimal. This minimal impact 
indicates that providers were already successfully identifying HIV-infected persons without 
the intervention. Increases in case detection rates attributable to the intervention were 
observed in populations with increased HIV testing (females) and populations that reflect 
HIV epidemic trends in North Carolina (non-Hispanic blacks).  
The small magnitude of the increase in HIV testing is consistent with evaluations of 
HIV testing programs in other settings with high baseline levels of HIV testing. In a single 
Denver STD clinic, HIV testing only increased 1.2% because 79% of patients tested for 
syphilis were already being tested for HIV before the intervention.63 Expectations of an HIV 
testing intervention’s magnitude should be tempered by the limits of the setting, which can 
be dictated by pre-existing HIV testing and case detection levels. 
The impact of expanded HIV testing programs on case detection is inconclusive. 
Interventions have led to both increases and decreases in case detection.7,9,13,62,63,65,110-112 
By examining the trajectory of case detection for over 2 years prior to the intervention, we 
were able to detect a declining trend prior to the intervention. This decline was followed by a 
steady rate of case detection during the post-intervention phase, driven by increased 
diagnoses in certain population groups.  
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Nearly all extant evaluations of HIV testing programs reduced the pre-intervention 
level of HIV testing and case detection to a cross-sectional measure. A program in San 
Francisco was evaluated with a dynamic pre-intervention comparison, but was implemented 
in an urban setting with a low level of pre-intervention HIV testing and lacked 
generalizability.112 A static measure of baseline HIV testing would not adequately capture 
pre-existing trends in HIV testing or case detection. In our evaluation, using a cross-
sectional or aggregate measure of HIV testing without adjusting for calendar year 
overestimated the impact of an HIV testing intervention. An aggregate measure of case 
detection underestimated the impact of the intervention, even showing a spurious negative 
association.  
Interrupted time series and multilevel regression analyses answer complementary 
research questions. Interrupted time series analysis addresses the change in the rate of an 
outcome over time and is an ecologic method; the unit of analysis is the cross-sectional 
calendar month. Although we urge caution in the over-interpretation of ecologic analyses, 
the agreement between the interrupted time series and multilevel regression models 
including calendar year strengthens our confidence in the interrupted time series results. We 
could not directly account for unmeasured covariates, such as changing perceptions of HIV, 
HIV-related stigma, and shifting disease dynamics. However, our study’s “quasi-
experimental” design should account for many unmeasured covariates. 
The use of routinely-collected public health surveillance data allowed us to evaluate 
this intervention throughout North Carolina, without redirecting resources from public health 
activities. This rich data source led to a larger study population than would have been 
feasible in a standard research environment or if analyses were restricted to a single clinical 
facility. However, surveillance data are not collected for research purposes and the 
completeness and accuracy of records and data elements cannot be verified. 
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Despite the disproportionately high burden of HIV in the southeastern United States, 
this study is the first to evaluate an expanded HIV testing program in the region using a 
comparison group.54,72-75 HIV prevention interventions in the South face unique challenges 
due to the high rates of comorbid conditions, socioeconomic disparities, and a stark contrast 
between urban and rural areas, which contribute to HIV-related stigma and difficulty 
accessing HIV medical care.76  
In North Carolina STD clinics, the introduction of a routine, opt-out expanded HIV 
testing program did not significantly alter the trajectory of HIV testing or case detection. 
Given the bounded nature of these outcomes, these results are not surprising. We believe 
that, due to the increased population eligible for HIV testing, this intervention allowed for the 
HIV testing saturation point to settle at higher level than would be observed without the 
intervention. We also identified slight increases in case detection that mitigated a pre-
intervention decline in identification of new HIV-infected cases. As HIV testing of the 
highest-risk populations was already very successful in the STD clinics, the incremental 
impact of expanding testing to lower-prevalence populations was marginal.  
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Tables and Figures 
Table 4.1: Demographic and Clinic-Level Characteristics of Persons Tested for HIV in 
North Carolina STD Clinics, July 2005 through June 2011 
  
Total 
 
N=402,774 
Pre-Intervention 
(7/2005-10/2007) 
N=128,029 
Post-Intervention 
(11/2007-6/2011) 
N=274,745 
   n  (%)  n  (%)  n  (%) 
Result             
New Positive         1,242  (0.31)            426  (0.33)            816  (0.30) 
Not New Positive    401,532  (99.69)    127,603  (99.67)    273,929  (99.70) 
Patient Covariates             
Gender             
Male    185,714  (46.11)       61,743  (48.23)    123,971  (45.12) 
Female    217,060  (53.89)       66,286  (51.77)    150,774  (54.88) 
Race/Ethnicity             
White Non-Hispanic    116,230  (28.86)       39,342  (30.73)       76,888  (27.99) 
Black Non-Hispanic    228,538  (56.74)       68,081  (53.18)    160,457  (58.40) 
Hispanic       35,126  (8.72)       11,113  (8.68)       24,013  (8.74) 
Other       22,880  (5.68)         9,493  (7.41)       13,387  (4.87) 
Age (years)             
18-24    179,780  (44.64)       56,961  (44.49)    122,819  (44.70) 
25-34    129,717  (32.21)       40,803  (31.87)       88,914  (32.36) 
35-44       57,295  (14.23)       18,908  (14.77)       38,387  (13.97) 
45-64       35,982  (8.93)       11,357  (8.87)       24,625  (8.96) 
Clinic Covariates             
Metropolitan Status*             
Metropolitan    300,266  (74.55)       96,327  (75.24)    203,939  (74.23) 
Micropolitan       81,054  (20.12)       25,427  (19.86)       55,627  (20.25) 
Neither       21,454  (5.33)         6,275  (4.9)       15,179  (5.52) 
Population Density#             
<199    135,938  (33.75)       42,106  (32.89)       93,832  (34.15) 
200-399       81,262  (20.18)       26,025  (20.33)       55,237  (20.1) 
400-599       31,048  (7.71)       10,602  (8.28)       20,446  (7.44) 
≥600    154,526  (38.37)       49,296  (38.5)    105,230  (38.3) 
% Below Poverty Line             
<15%       70,298  (17.45)       23,275  (18.18)       47,023  (17.12) 
15-19.9%    250,865  (62.28)       79,907  (62.41)    170,958  (62.22) 
20-24.9%       59,706  (14.82)       17,772  (13.88)       41,934  (15.26) 
≥25%       21,905  (5.44)         7,075  (5.53)       14,830  (5.4) 
In-House HIV Clinic             
Yes       83,850  (20.82)       27,603  (21.56)       56,247  (20.47) 
No    318,924  (79.18)    100,426  (78.44)    218,498  (79.53) 
Baseline HIV Rate (2005-
2007)^     
        
0-4.9       18,353  (4.56)         5,912  (4.62)       12,441  (4.53) 
5-9.9       62,317  (15.47)       19,975  (15.6)       42,342  (15.41) 
10-14.9       78,829  (19.57)       25,595  (19.99)       53,234  (19.38) 
≥15    243,275  (60.40)       76,547  (59.79)    166,728  (60.68) 
*Defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
^Calculated as the average reported HIV case rate per 100,000 population 2005-2007 
#per square mile 
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Figure 4.1: Interrupted Time Series Analysis of Overall Monthly Trends in (a) the Number 
of HIV Tests, (b) the Number of HIV Tests per 100,000 Population, (c) the Number of New 
HIV-Infected Cases, and (d) the New HIV-Positivity per 1,000 HIV Tests in North Carolina 
STD Clinics, July 2005 through June 2011 
 
a) b) 
   
c)             d) 
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Table 4.2: Monthly Change in the Rate of HIV Tests per 100,000 Population in North 
Carolina STD Clinics Attributable to the North Carolina Expanded HIV Testing 
Program, July 2005-June 2011 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*MD: Mean Difference, 95% CI: 95% confidence intervals 
MeSA/MiSA: defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
Baseline HIV (2005-2007): calculated as the average reported HIV case rate per 100,000 population 2005-2007 
Population density: per square mile  
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Table 4.3: Monthly Change in the Rate of New HIV-Positivity per 1,000 HIV Tests 
Performed in North Carolina STD Clinics Attributable to the North Carolina Expanded 
HIV Testing Program, July 2005-June 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*MD: Mean Difference, 95% CI: 95% confidence intervals 
MeSA/MiSA: defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
Baseline HIV (2005-2007): calculated as the average reported HIV case rate per 100,000 population 2005-2007 
Population density: per square mile 
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Table 4.4: Overall Impact of North Carolina Expanded HIV Testing Program on HIV-
Positivity using County-Specific Random Intercept Multilevel Regression, North 
Carolina STD Clinics, July 1, 2005 through June 30, 2011 
  County Random Intercept 
  Post-Intervention 3-month Lag Period 
  OR (95% CI) OR (95% CI) 
Unadjusted     
Post-Intervention 0.90 (0.80, 1.01) 0.88 (0.64, 1.21) 
Pre-Intervention 1.00 1.00 
Patient Covariates^     
Post-Intervention 0.92 (0.82, 1.04) 0.89 (0.65, 1.23) 
Pre-Intervention 1.00 1.00 
Clinic Covariates#     
Post-Intervention 0.90 (0.80, 1.01) 0.88 (0.64, 1.21) 
Pre-Intervention 1.00 1.00 
Patient + Clinic Covariates     
Post-Intervention 0.92 (0.82, 1.04) 0.89 (0.65, 1.23) 
Pre-Intervention 1.00 1.00 
      
Year     
Post-Intervention 1.13 (0.57, 2.23) 1.02 (0.69, 1.52) 
Pre-Intervention 1.00 1.00 
Patient Covariates + Year     
Post-Intervention 1.16 (0.59, 2.28) 1.04 (0.70, 1.55) 
Pre-Intervention 1.00 1.00 
Clinic Covariates + Year     
Post-Intervention 1.12 (0.57, 2.21) 1.02 (0.68, 1.51) 
Pre-Intervention 1.00 1.00 
Patient + Clinic Covariates + Year     
Post-Intervention 0.92 (0.82, 1.04) 0.89 (0.65, 1.23) 
Pre-Intervention 1.00 1.00 
 OR: odds ratio; 95% CI: 95% confidence interval 
^Patient covariates include gender, race/ethnicity, and age 
#Clinic covariates include metropolitan status, population density, % below poverty line, affiliated HIV clinic, and 
baseline HIV rate 
  
   
CHAPTER 5: RISK OF PROGRESSION TO AIDS AMONG NEWLY-DIAGNOSED HIV-
INFECTED PERSONS BEFORE AND AFTER THE INTRODUCTION OF A ROUTINE, 
OPT-OUT HIV TESTING PROGRAM IN NORTH CAROLINA SEXUALLY-TRANSMITTED 
DISEASE CLINICS 
 
Introduction 
Persons who do not perceive themselves to be at risk for acquiring HIV infection may 
not seek HIV testing, leading to delays in HIV diagnosis.118 Delays in HIV diagnosis, and 
subsequent delays in treatment, can lead to poor health and decreased quality of life, as 
well as a greater chance of transmission to others.18,22 Approximately 50% of new HIV 
infections in the United States each year are attributable to the 20% of persons living with 
HIV who are unaware of their infection.3,5 
In 2006, the Centers for Disease Control and Prevention (CDC) recommended 
routine, opt-out HIV testing in clinical settings to provide HIV testing services to all persons, 
regardless of self- or provider-perceived risk.1 By reducing “missed opportunities” for HIV 
testing in clinical settings, the goal of these recommendations was to increase status 
awareness and identify HIV-infected persons earlier in the course of infection.1,16 
Despite these recommendations, many persons continue to be diagnosed with HIV 
infection late in the course of disease. Nationally, 32.5% of persons diagnosed with HIV 
develop AIDS within 1 year of their HIV diagnosis.15 In the absence of HIV therapy, most 
HIV-infected persons progress to clinical AIDS within 10 years of HIV seroconversion.27 
Therefore, persons who progress to AIDS within 1 year of their HIV diagnosis could have 
been infected with HIV but unaware of their infection for approximately 9 years. Late HIV 
diagnosis is most common among males, persons of older ages, racial/ethnic minorities and 
those infected via heterosexual transmission.119-121 These subgroups may experience 
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barriers in accessing healthcare, HIV-related stigma, and low perceived risk of HIV 
acquisition. 
The impact of routine, opt-out HIV testing programs regarding program impact on 
immunologic status at diagnosis are inconclusive.7,8,11,13,66,67 However, these evaluations 
were limited in their scope to HIV testing programs in single facilities, were not linked with 
surveillance data, and could not describe disease progression following diagnosis. 
We conducted a statewide evaluation of the impact of a routine HIV testing program 
on the risk of progression to AIDS of newly-identified HIV-infected persons in North Carolina 
sexually transmitted disease (STD) clinics. We aimed to determine if this routine, opt-out 
HIV testing program successfully reached the population of persons who do not perceive 
themselves to be at risk for HIV acquisition and would otherwise not seek HIV testing. 
 
Methods 
Study Population and Setting 
This study included all North Carolina residents aged 18-64 who were identified as 
new HIV-infected cases in North Carolina STD clinics from July 1, 2005 through June 30, 
2011.  
A new HIV-infected case was defined as a person with a positive HIV test result in 
the same calendar month as the person’s surveillance-recorded HIV diagnosis date. HIV 
test and HIV/AIDS diagnosis dates were abstracted from the electronic HIV/AIDS reporting 
system (eHARS), the surveillance database of all HIV-infected persons in North Carolina. 
The HIV testing protocol in the North Carolina STD clinics has been described in 
detail elsewhere (Chapter 3). Briefly, blood samples and demographic information were 
collected for patients who agreed to HIV testing and processed in the North Carolina State 
Laboratory for Public Health (SLPH). All test results and demographic information were 
entered into the SLPH database and results were provided to patients. If a person tested 
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positive and no previous record existed in eHARS, the patient was entered into the 
surveillance system as a new case of HIV. Patient-level data were collected by linking the 
SLPH and eHARS electronic surveillance systems in December 2012, allowing for at least 
18 months of follow-up data on all HIV-infected persons. 
 
Intervention: Expanded HIV Testing Program 
In November 2007, the North Carolina expanded HIV testing program was 
introduced, in conjunction with a modification of the state’s administrative code to allow for 
routine, opt-out HIV testing. This HIV testing program included guidelines for routine HIV 
screening in North Carolina STD clinics. Since the patient population in STD clinics is at a 
high risk for HIV acquisition, HIV testing was already performed frequently.113 This analysis 
focuses on the incremental impact of offering routine HIV screening to all STD clinic 
patients. 
 
Exposure Definition 
The intervention was implemented on November 1, 2007. All new HIV-infected cases 
identified before this date were considered “unexposed” to the intervention, those tested 
after were “exposed”. In sensitivity analyses, we explored the inclusion of 3- or 6-month lag 
periods to allow for full implementation of the intervention (Table A3.5). 
 
Outcome Assessment 
“Late HIV diagnosis” is a broad term that describes persons who were diagnosed in, 
or quickly progressed to, an immune-compromised HIV-related state. Using the dates of HIV 
and AIDS diagnosis from eHARS, we constructed 4 definitions that capture progression to 
AIDS. AIDS diagnosis was dependent on clinical presentation with an opportunistic infection 
or a measured CD4 count <200 (or 14%).40  
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The primary outcome definition was chosen, in agreement with CDC definitions, to 
be an AIDS diagnosis within 12 months of HIV diagnosis.15 Three additional definitions were 
also considered: AIDS within 1 month, 6 months, and 18 months. To account for possible 
reporting delays and for persons lacking an exact date of HIV diagnosis, a 15 day period 
was added to each outcome definition (1 month + 15 days, 6 months + 15 days, etc.). 
 
Covariate Assessment 
Patient-level covariates were abstracted from the SLPH databases at the date of HIV 
testing and included gender (male, female), race/ethnicity (non-Hispanic white, non-Hispanic 
black, Hispanic, other), age and previous HIV testing (yes, no). A covariate that combined 
information on both the patient’s gender and self-reported sexual risk factors was created 
(female, heterosexual male, men who have sex with men [MSM]). Sexual risk factors, 
particularly identifying MSM, were selected for inclusion because the majority of HIV 
transmission in North Carolina is driven by heterosexual and MSM transmission.40  
Clinic-level covariates were abstracted from publically-available datasets and 
included population density (<199, 200-399, 400-599, ≥600 persons per square mile), 
metropolitan/micropolitan statistical areas (MeSA, MiSA, neither), and proportion of the 
county living below the poverty line (<15%, 15-19.9%, 20-24.9%, ≥25%).95-97 To account for 
underlying burden of HIV in each county, the number of reported HIV cases per 100,000 
persons were averaged from 2005 through 2007 to determine a baseline HIV rate 
(categorized for analysis as <10, 10-14.9, ≥15).115 A covariate that identified STD clinics that 
housed a clinic dedicated to HIV care (Durham, Mecklenberg, and Wake Counties) was also 
created. 
 
 
 
61 
 
Statistical Analyses 
Descriptive analyses were used to examine overall trends in late HIV diagnosis 
before and after the introduction of the expanded HIV testing program. The association 
between the introduction of the intervention and risk of progression to AIDS was examined 
with multilevel regression models to account for STD clinic clustering using a random-
intercept term unique to each STD clinic. In sensitivity analyses, these fixed-slope random 
intercept models were compared with models that do not allow for clustering between clinics 
(Table A3.4). We used binomial regression models calculate risk differences (RDs) and risk 
ratios (RRs), with corresponding 95% confidence intervals (95% CIs) for progression to 
AIDS. 
Based on national surveillance data showing that the overall risk of late HIV 
diagnosis has not changed drastically over time, we assumed that we would not observe a 
time trend in our outcomes beyond the impact of our dichotomized intervention.15,122,123 
However, in sensitivity analyses, we also tested models that broadly account for temporal 
trends in over the study period using both indicator variables and a linear term for study year 
(Table A3.2). 
As the intervention (exposure) was determined externally and implemented uniformly 
across North Carolina, the intervention should be independent of all patient- and clinic-level 
covariates. Over the study period, there were no significant changes in HIV-related 
definitions, clinical practice, or policies. This quasi-experimental design should negate 
traditional confounders. Nonetheless, we examined the impact of accounting for patient- and 
clinic-level covariates in multivariate regression. 
In addition to the overall effect of the intervention on late diagnosis, we examined the 
impact of the intervention in strata of patient (gender, gender/risk, race/ethnicity, age, 
previous HIV test), and clinic (metropolitan status, population density quartiles, percent 
below poverty line quartiles, affiliated HIV clinic, baseline HIV case rate tertiles) subgroups. 
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Stratified estimates were compared using confidence limit ratios and interaction terms were 
evaluated using likelihood ratio tests at an a priori alpha level of 0.10. 
All statistical analyses were performed in SAS version 9.2.106 The study was 
approved by the University of North Carolina at Chapel Hill Institutional Review Board. 
 
Results 
From July 1, 2005 through June 30, 2011, 1203 persons were identified as new HIV-
infected cases in North Carolina STD clinics. Of these persons, 12% and 13% were 
diagnosed with AIDS within 12 months of their initial HIV diagnosis in the pre- and post-
intervention periods, respectively (Tables 5.1). Approximately 5% of persons were 
diagnosed with AIDS within 1 month of their HIV diagnosis and over 14% of persons were 
diagnosed with AIDS within 18 months of their HIV diagnosis (Table 5.2). 
Nearly 80% of newly-diagnosed persons were male, including approximately 45% 
MSM (Table 5.1). Over 65% of HIV-infected persons were non-Hispanic black and 35% 
were under 25 years of age at the time of their HIV diagnosis. Over 70% of newly-diagnosed 
HIV-infected persons reported an HIV testing experience prior to their diagnosis. 
The proportion of male HIV-infected cases increased over the study period, from 
75% in the pre-intervention period to 82% in the post-intervention period. The proportion of 
non-Hispanic black persons increased from 61% to 70%, with a decline in the proportion of 
persons of other racial and ethnic backgrounds. A larger proportion of HIV-infected persons 
were diagnosed in low population density counties (<199 per square mile) in the post-
intervention period, compared with the pre-intervention period (pre-intervention: 18%, post-
intervention: 28%). 
Overall, we did not observe evidence of an association between the introduction of 
the expanded HIV testing program and the risk of progression to AIDS within 12 months of 
HIV diagnosis (Table 5.3). Compared with the pre-intervention period, the risk of 
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progression to AIDS within 12 months of HIV diagnosis was 0.006 higher (RD = 0.006, 95% 
CI: -0.033, 0.044), or 1.04 times greater (RR = 1.04, 95% CI: 0.77, 1.43), in the post-
intervention period. Since adjustment for patient- and clinic-level characteristics did not alter 
the results, we found little evidence for confounding by measured covariates. Adjustment for 
calendar year of HIV testing also did not change the estimates, but was accompanied by a 
loss of precision (Table A3.2). Point estimates of the risk ratios differed slightly with each 
definition of “late HIV diagnosis”, the overall substantive interpretation of the results did not 
change. However, the intervention was associated with a slight increase in risk of 
progression to AIDS within 1 month of HIV diagnosis (RR = 1.23, 95% CI: 0.75, 2.01). 
Although we did not observe an overall association between the intervention and the 
risk of late diagnosis in the entire study population, stratification by patient-level 
characteristics suggested differences by subgroups (Table 5.4). Among women, the 
introduction of the intervention was associated with an increased risk of progression to AIDS 
(RR=2.32, 95% CI: 1.06, 4.83). Further analysis revealed that the risk progression to AIDS 
among women was relatively low in the pre-intervention period, peaked in 2008 and 2009, 
then slightly decreased in 2010 and 2011(Table A3.7). Among men, the introduction of the 
intervention was associated with a slight decrease in risk of progression to AIDS (RR=0.86, 
95% CI: 0.61, 1.22). 
Persons who, according to self-report, had previously been tested for HIV were 
different from those who had not previously been tested. The intervention was associated 
with an increase in late HIV diagnosis among persons who had previously been tested for 
HIV (RR=1.42, 95% CI: 0.92, 2.19), but a decrease among persons who had not been 
previously tested for HIV (RR=0.67, 95% CI: 0.43, 1.06). 
As the definition of late HIV diagnosis was broadened to AIDS within 6 months of 
HIV diagnosis and beyond, these stratum-specific differences were attenuated towards the 
null. Stratification by other patient- and clinic-level covariates did not identify other 
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population subgroups with unique associations between the intervention and late HIV 
diagnosis (Table A3.6). 
 
Discussion 
The CDC’s recommendations for routine, opt-out HIV testing were driven by a desire 
to increase status awareness and diagnose persons earlier in the course of infection by 
reducing missed HIV testing opportunities in clinical settings.1,16 Following these 
recommendations and the introduction of many expanded HIV testing programs, the impact 
of HIV testing interventions on the timing of HIV diagnosis is unclear.7,8,11,13,66,67 In North 
Carolina STD clinics, the introduction of a routine, opt-out expanded HIV testing program did 
not change the risk of progression to AIDS. 
Although no overall association was detected between the intervention and 
progression to AIDS, stratification by gender and previous HIV testing status revealed 
important associations. Among women, the intervention was associated with an increased 
risk of progression to AIDS. Women are not traditionally seen as particularly high-risk for 
HIV acquisition; in the absence of HIV testing interventions, men are more often diagnosed 
in poorer immunological states than women .16,86,107,108,119,120,123-126 
This intervention may have succeeded in identifying women with advanced HIV 
disease who would otherwise have not been identified in STD clinics, but would have been 
identified in urgent care or emergency settings. After an initial post-intervention surge in late 
diagnoses, we would expect this effect to dissipate. Our results support this hypothesis – we 
observed an increase in the risk of late diagnosis among women in 2008 and 2009, 
immediately after the intervention. In 2010 and 2011, the risk of late diagnosis decreased, 
but still settled above pre-intervention levels. 
In general, persons testing for HIV in the STD clinic were not naïve to HIV testing; 
over 70% self-reported a previous HIV test. Although this high level of exposure to HIV 
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testing may seem promising, among persons self-reporting a previous HIV test, this HIV 
testing intervention was associated with an increased risk of progression to AIDS. Persons 
who tested negative on a previous HIV test may feel immune to HIV and continue to engage 
in risky sexual behavior, while delaying further HIV testing.25,127-129 This delay in HIV testing 
could result in an arti-factual increase in late diagnoses in the period immediately following 
the introduction of the intervention. 
Among persons who did not report a previous HIV test, the intervention was 
associated with a decrease in the risk of progression to AIDS. These persons may not have 
perceived themselves to be at risk for HIV acquisition, failed to seek out HIV testing, or may 
not have been identified in risk-based HIV testing.30,130 This result supports the CDC’s 
hypothesis: if persons are offered HIV testing routinely, they will be detected earlier in the 
course of infection. 
Previous HIV testing status was based on self-report, which may not accurately 
capture previous HIV testing history.128,131 Despite this potential for misclassification, self-
reported HIV testing history would be more closely linked with self-perceived HIV risk than 
with actual HIV testing history. If a patient previously visited a clinical facility and had blood 
drawn but was not informed of an HIV test result, the patient may incorrectly assume that 
he/she tested negative for HIV .132 Alternatively, a patient may forget that he/she received an 
HIV test in a previous medical encounter.128 
Routine HIV testing programs in emergency departments have been evaluated for 
impact on immunologic status at diagnosis, but yield inconclusive results. In Oakland, 
California, the proportion of persons concurrently diagnosed with AIDS increased with the 
introduction of opt-out HIV testing; in Denver Colorado, the proportion of persons diagnosed 
with a CD4 count < 350 decreased with a routine HIV testing intervention.7,13 However, 
these evaluations were limited by very small numbers of HIV-infected persons and reliance 
only on laboratory data immediately following HIV diagnosis. Our study expands upon these 
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previous evaluations with a statewide analysis using surveillance data to capture 
progression to AIDS in any clinical facility in North Carolina. 
The use of surveillance data allowed us to evaluate this research question statewide, 
without redirecting limited public health resources. Surveillance data are collected for public 
health, not research, purposes and we cannot verify the accuracy or completeness of the 
data. The date of AIDS diagnosis was used to determine whether the patient had 
progressed to AIDS within a specific time period. This measure depended upon the patient 
seeking contact with a medical provider to receive an AIDS diagnosis, and the subsequent 
reporting of this diagnosis. Although many HIV-infected persons do not seek routine HIV 
medical care, the symptoms associated with progression to AIDS should prompt most 
persons to seek medical attention, which would lead to inclusion in our dataset.3  
Nationally, 32.5% of persons are diagnosed with AIDS within 12 months of their 
initial HIV diagnosis; in North Carolina, 26.1% progress to AIDS within 6 months.15,40 
Consistent with national data of late diagnosis and data from other states, we observed a 
low proportion of STD clinic patients presenting as late diagnoses, with 10.8% progressing 
to AIDS within 6 months of HIV diagnosis.15,66,108,133,134 This low prevalence of late HIV 
diagnosis may be attributable to the generally high-risk status of the patients attending STD 
clinics, patients with frequent HIV testing during follow-up STD clinic visits, and increased 
provider awareness of the importance of HIV testing.113,127 
The success of the CDC recommendations and resultant routine HIV screening 
programs hinge on the assumption that persons often diagnosed late in the course of their 
HIV infect have prior clinical visits, or “missed opportunities” for HIV testing.1 Each missed 
opportunity is a potential intervention point for HIV testing to reduce the proportion of late 
diagnoses. Routine HIV testing aims to eliminate those missed opportunities and, using a 
structural intervention, ensure that persons with low self-perceived HIV risk have access to 
HIV testing services. 
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In this study, the overall proportion of persons progressing to AIDS over time did not 
change with the introduction of a routine, opt-out HIV testing program. This result indicates 
that the intervention was not successful in identifying the subset of persons who often 
present late for HIV testing. Contrary to the intentions of routine, opt-out HIV testing, we 
observed an increase in the risk of progression to AIDS among women and persons with a 
previous HIV test. Although persons who quickly progressed to AIDS comprised a small 
proportion of all new HIV diagnoses from the STD clinic, the lack of change in this proportion 
with this routine HIV testing intervention highlights that these persons do not regularly 
access the STD clinic healthcare system. Persons who do not seek interactions with the 
health care system cannot benefit from routine HIV testing programs in clinical settings. 
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Tables and Figures 
Table 5.1: Demographic and Clinic-Level Characteristics of Newly-Identified HIV-
Infected Persons in North Carolina STD Clinics, July 2005 through June 2011 
  
Total 
 
N=1203 
Pre-Intervention 
(7/2005-10/2007) 
N=422 
Post-Intervention 
(11/2007-6/2011) 
N=781 
  n (%) n (%) n (%) 
Progression to AIDS within 1 year             
Yes 154 (12.8) 52 (12.3) 102 (13.0) 
No 1049 (87.2) 374 (88.7) 679 (86.9) 
Clinic Characteristics             
Metropolitan Status*             
Metropolitan 958 (79.6) 350 (82.9) 608 (77.8) 
Micropolitan 198 (16.5) 64 (15.2) 134 (17.2) 
Neither 47 (3.9) 8 (1.9) 39 (5.0) 
Population Density per square mile             
<199 297 (24.7) 78 (18.5) 219 (28.0) 
200-399 191 (15.9) 71 (16.8) 120 (15.4) 
400-599 163 (13.5) 65 (15.4) 98 (12.6) 
≥600 522 (45.9) 208 (49.3) 344 (44.0) 
% Below Poverty Line             
<15% 234 (19.4) 96 (22.8) 138 (17.7) 
15-19.9% 755 (62.8) 272 (64.4) 483 (61.8) 
20-24.9% 158 (13.1) 40 (9.5) 118 (15.1) 
≥25% 56 (4.7) 14 (3.3) 42 (5.4) 
Affiliated HIV Clinic             
Yes 340 (28.3) 127 (30.1) 213 (27.3) 
No 863 (71.7) 295 (69.9) 568 (72.7) 
Baseline HIV Rate (2005-2007)^           
<10 145 (12.0) 48 (11.4) 97 (12.4) 
10-14.9 173 (14.4) 56 (13.3) 117 (15.0) 
≥15 885 (73.6) 318 (75.3) 567 (72.6) 
*Defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
^Calculated as the average reported HIV case rate per 100,000 population 2005-2007 
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Table 5.2: Progression to AIDS After Initial HIV Diagnosis, Base and Alternative 
Definitions, among Newly-Identified HIV-Infected Persons in North Carolina STD 
Clinics, July 1, 2005 through June 30, 2011 
  
Total 
 
n=1203 
Pre-Intervention 
(7/2005-10/2007) 
n=422 
Post-Intervention 
(11/2007-6/2011) 
n=781 
  n (%) n (%) n (%) 
Base Definition             
AIDS within 12 months             
Yes 154 (12.80) 21 (4.98) 49 (6.27) 
No 1049 (87.20) 401 (95.02) 732 (93.73) 
Alternative Definitions             
AIDS within 1 months             
Yes 70 (5.82) 47 (11.14) 83 (10.63) 
No 1133 (94.18) 375 (88.86) 698 (89.37) 
AIDS within 6 months             
Yes 130 (10.81) 52 (12.32) 102 (13.06) 
No 1073 (89.19) 370 (87.68) 679 (86.94) 
AIDS within 18 months             
Yes 171 (14.21) 61 (14.45) 110 (14.08) 
No 1032 (85.79) 361 (85.55) 671 (85.92) 
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Table 5.3: Unadjusted and Adjusted Associations between the Expanded HIV Testing 
Program and Risk of Progression to AIDS using County-Specific Random Intercept 
Regression Models 
  Base Definition   Alternative Definitions 
  
AIDS within  
12 months   
AIDS within  
1 month 
AIDS within  
6 months 
AIDS within  
18 months 
Adjustment Set RR (95% CI)*   RR (95% CI)* RR (95% CI)* RR (95% CI)* 
Unadjusted           
Post-Intervention 1.05 (0.77, 1.43)   1.23 (0.75, 2.01) 0.95 (0.67, 1.33) 0.97 (0.72, 1.29) 
Pre-Intervention 1.00   1.00 1.00 1.00 
Patient Covariates           
Post-Intervention 0.99 (0.72, 1.36)   1.19 (0.72, 1.95) 0.91 (0.65, 1.29) 0.91 (0.68, 1.21) 
Pre-Intervention 1.00   1.00 1.00 1.00 
Clinic Covariates           
Post-Intervention 1.01 (0.74, 1.39)   1.22 (0.74, 2.01) 0.91 (0.65, 1.28) 0.93 (0.69, 1.24) 
Pre-Intervention 1.00   1.00 1.00 1.00 
Patient + Clinic 
Covariates           
Post-Intervention 0.96 (0.70, 1.32)   1.17 (0.70, 1.94) 0.89 (0.63, 1.25) 0.87 (0.65, 1.17) 
Pre-Intervention 1.00   1.00 1.00 1.00 
*RR = risk ratio for progression to AIDS within specified time period for persons diagnosed after the introduction 
of a routine HIV testing intervention (exposed) vs. before (unexposed) 
^Patient covariates include gender, race/ethnicity, age, and self-reported previous HIV test 
#Clinic covariates include metropolitan status, population density, % below poverty line, affiliated HIV clinic, and 
baseline HIV rate 
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Table 5.4: Association between the Expanded HIV Testing Program and Risk of 
Progression to AIDS, Stratified by Patient-Level Characteristics 
 Base Definition  Alternative Definitions 
  
AIDS within  
12 months   
AIDS within  
1 month 
AIDS within  
6 months 
AIDS within  
18 months 
  RR* (95% CI)   RR* (95% CI) RR* (95% CI) RR* (95% CI) 
Overall 1.05 (0.77, 1.43)   1.23 (0.75, 2.01) 0.95 (0.67, 1.33) 0.97 (0.72, 1.29) 
Stratified Estimates           
Gender           
Male 0.86 (0.61, 1.22)   0.98 (0.57, 1.69) 0.77 (0.53, 1.11) 0.84 (0.61, 1.16) 
Female 2.26 (1.06, 4.83)   3.00 (0.88, 10.27) 2.17 (0.95, 4.93) 1.66 (0.86, 3.24) 
Risk Group w/ Gender           
Female 2.26 (1.06, 4.83)   3.01 (0.88, 10.31) 2.17 (0.96, 4.94) 1.66 (0.85, 3.24) 
Male Heterosexual 0.78 (0.48, 1.26)   0.89 (0.41, 1.95) 0.75 (0.44, 1.27) 0.77 (0.48, 1.22) 
MSM 0.93 (0.57, 1.53)   1.07 (0.49, 2.31) 0.77 (0.46, 1.31) 0.89 (0.57, 1.40) 
Race/Ethnicity           
White Non-Hispanic 0.76 (0.35, 1.64)   0.92 (0.29, 2.92) 0.71 (0.32, 1.56) 0.69 (0.32, 1.46) 
Black Non-Hispanic 1.23 (0.82, 1.83)   1.70 (0.86, 3.35) 1.09 (0.70, 1.70) 1.10 (0.77, 1.58) 
Hispanic 0.56 (0.21, 1.52)   0.22 (0.05, 1.00) 0.56 (0.21, 1.51) 0.49 (0.19, 1.28) 
Other 1.08 (0.37, 3.20)   *NE 1.36 (0.42, 4.36) 1.08 (0.37, 3.20) 
Age (years)           
18-24 1.24 (0.68, 2.24)   1.78 (0.67, 4.72) 1.13 (0.60, 2.12) 1.21 (0.70, 2.10) 
25-34 1.01 (0.58, 1.78)   1.02 (0.45, 2.30) 0.94 (0.51, 1.74) 0.91 (0.54, 1.54) 
35-44 1.12 (0.54, 2.34)   4.15 (0.52, 33.22) 1.11 (0.51, 2.43) 0.86 (0.44, 1.70) 
45-64 0.80 (0.42, 1.51)   0.65 (0.26, 1.62) 0.61 (0.30, 1.26) 0.81 (0.44, 1.48) 
Previous HIV Test           
Yes 1.42 (0.92, 2.19)   1.96 (0.95, 4.03) 1.38 (0.86, 2.22) 1.19 (0.81, 1.76) 
No 0.67 (0.43, 1.06)   0.69 (0.34, 1.40) 0.57 (0.35, 0.93) 0.69 (0.45, 1.07) 
*RR = risk ratio for progression to AIDS within specified time period for persons diagnosed after the introduction 
of a routine HIV testing intervention (exposed) vs. before (unexposed), not adjusted for patient- or clinic-level 
covariates 
Bold = statistically significant interaction term by likelihood ratio test at an a prior alpha level of 0.10 
NE = not-estimable due to small numbers 
  
   
CHAPTER 6: CONCLUSION 
Approximately 20% of the 1.1 million persons infected with HIV in the United States 
are unaware of their HIV infection; these persons contribute to nearly 50% of new HIV 
transmission events each year.3-5 To increase awareness of HIV status and identify HIV-
infected persons earlier in infection, the CDC released revised recommendations for routine, 
opt-out HIV testing in clinical settings.1 From 2007 through 2010, over 1.8 million HIV tests 
were conducted under the CDC’s expanded HIV testing initiative, yielding 18,000 new HIV 
diagnoses (0.7% positivity).2 However, these new diagnoses only represent a fraction of the 
approximately 150,000 new transmission events during the same period.6 
Despite widespread implementation of these recommendations in clinical settings, 
the impact of these interventions is inconclusive.7,8,11-13 Extant program evaluations are 
limited by descriptive analyses, small numbers, and a focus on emergency departments and 
clinical settings in major metropolitan centers. These evaluations are not generalizable, 
especially not to the southeastern United States, which bears a disproportionate burden of 
HIV infection.14 
We evaluated the impact of a routine, opt-out HIV testing program in North Carolina 
STD clinics with a high pre-intervention baseline level of HIV testing for (a) HIV testing, (b) 
case detection, and (c) progression to AIDS among newly diagnosed persons. Using a 
before-after intervention analysis, we examined the impact of this intervention in the context 
of underlying temporal trends. We used statewide HIV surveillance data, resulting in an 
extremely large study population that was generalizable to STD clinic patients in the entire 
southeastern region of the United States. Overall, due to high levels of HIV testing success 
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prior to the intervention, the incremental benefit of this expanded HIV testing program was 
minimal. 
 
Summary of Findings 
HIV Testing 
Although the rate of HIV testing increased post-intervention, the increase was less 
than what was observed prior to the intervention. Prior to the intervention, the number of HIV 
tests performed per month increased at a rate of 55 tests per month (95% CI: 41, 72), or an 
increase of 0.81 tests per 100,000 persons per month. Post-intervention, the monthly 
increase in the number of tests slowed to 34 tests per month (95% CI: 26, 42), or an 
increase of 0.46 tests per 100,000 persons per month.  
Using aggregate measures of HIV testing pre- and post-intervention did not 
adequately capture the underlying trends in HIV testing over time, identifying a spurious 
increase in HIV testing with the intervention. However, after roughly accounting for time by 
adjusting for calendar year, the association was inverted and in agreement with our 
interrupted time series results described above. 
A decrease in the monthly rate of HIV testing attributable to the intervention was 
observed in most patient- and clinic-level strata. However, the monthly rate of HIV testing 
did not differ among two traditionally low-risk groups: females and non-Hispanic white 
patients. This lack of change in the monthly rate of HIV testing suggests continued HIV 
testing at a high level. 
 
Case Detection 
We observed little pre- or post-intervention temporal trend in the detection of new 
HIV-infected persons; the rate of HIV case detection was approximately 0.3% for the total 
study period. However, we did note a slight decrease in the rate of case detection prior to 
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the intervention, which was mitigated post-intervention. In the post-intervention period, the 
rate of case detection remained steady and did not increase or decrease. This mitigation 
was predominately driven by increases in the monthly rate of case detection attributable to 
the intervention among females and non-Hispanic black patients. These populations reflect 
epidemic trends in North Carolina (non-Hispanic blacks) and groups in which we saw 
continued increases in HIV testing rates (females).40 
Despite these subtle changes in the rates of case detection over time, aggregate 
pre- and post-intervention measures of HIV positivity showed a decrease in case detection 
with the introduction of the intervention (OR=0.89, 95% CI: 0.79, 1.00). After adjusting for 
calendar year of HIV testing, this association attenuated toward the null (OR=1.02, 95% CI: 
0.69, 1.52), indicating that the majority of the unadjusted association was due to underlying 
temporal trends. 
 
Progression to AIDS 
Overall, we did not observe any association between the introduction of a routine, 
opt-out HIV testing program in North Carolina STD clinics and the risk of progression to 
AIDS within 12 months of HIV diagnosis. This result was consistent across all definitions of 
“late HIV diagnosis”, from 6 month to 18 months. However, we did observe a slight positive 
association between the intervention and risk of progression to AIDS within 1 month of HIV 
diagnosis (RR = 1.23, 95 % CI: 0.75, 2.01). 
The intervention was associated with an increased risk of progression to AIDS 
among persons who had previously been tested for HIV, but a decrease among persons 
who had not been previously tested. Persons who had already been tested for HIV may feel 
immune to HIV infection, while continuing to engage in risky behavior.30,130 Among women, 
the introduction of the intervention was associated with an increased risk of progression to 
AIDS. 
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Interpretation of Results 
Due to the high pre-intervention rates of HIV testing and case detection in the North 
Carolina STD clinics, the overall impact of the intervention was marginal. HIV testing and 
case detection are bounded quantities; HIV testing is limited by the capacity and size of the 
clinical setting and case detection is limited by the clinic’s underlying HIV prevalence. 
Therefore, in a clinical setting with a high baseline level of HIV testing and case detection 
like an STD clinic, the maximum room for improvement is quite small. 
However, the greatest potential impact can be reached by sub-populations that were 
not adequately offered HIV testing prior to the intervention. In this analysis, the persons 
traditionally considered low-risk for HIV testing, particularly women, reaped the greatest 
benefit. Pre-intervention, HIV testing was focused on persons at highest risk for HIV 
acquisition based on risk behavior and potential for syphilis infection, groups mostly 
comprised of men. Women were not regularly targeted for HIV testing unless they presented 
with significant risk factors. Therefore, with the introduction of routine, opt-out HIV testing, 
the monthly rate of HIV testing among women in the STD clinics continued to increase 
rapidly and case detection rates attributable to the intervention also increased.  
The increased risk of progression to AIDS among women immediately following the 
introduction of the intervention suggests the identification of late-stage infected women who 
would otherwise have been identified in urgent care or emergency settings. This increase in 
late diagnoses is to be expected immediately after the introduction of an HIV testing 
intervention, when the “low hanging fruit” in the newly tested population is identified. With 
sustained routine HIV testing of this population over a longer period of time, we would 
expect attenuation of this association. 
Therefore, although the overall impact of this intervention was minimal, the 
introduction of this program partially accomplished the CDC’s goals of expanding HIV 
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testing services to all persons, regardless of risk. Risk-based testing often fails accurately 
identify high-risk persons and is especially troubling in a high-risk clinical setting, like an 
STD clinic.30 Because the greater increase in HIV testing was observed in low-risk persons 
with little undiagnosed HIV infection, we did not observe a corresponding increase in case 
detection. 
The risk of progression to AIDS did not change with the introduction of the 
intervention, except for a slightly elevated risk of progression to AIDS within 1 month of HIV 
diagnosis. Consistent with national data of late diagnosis and data from other states, we 
observed a low proportion of STD clinic patients presenting as late diagnoses with 10.8% 
progressing to AIDS within 6 months of HIV diagnosis. Nationally, persons diagnosed with 
HIV at STD clinics tend to have better immunological profiles than persons diagnosed in 
other clinical settings.15,66,108,133,134 This relatively low proportion of late diagnoses was most 
likely due to the high baseline levels of HIV testing in STD clinics and frequent HIV testing. 
By offering HIV testing at all clinical visits through routine HIV screening, the CDC 
hoped there would be fewer missed opportunities for HIV testing and persons would be 
identified earlier in infection. However, this noble goal of reducing missed opportunities 
hinges on the assumption that persons who are diagnosed late have interactions with the 
medical community before they develop clinical AIDS. The near constant level of late 
diagnoses in this study suggests that routine HIV screening in STD clinics is not a viable 
method to reach these individuals. Persons who visit STD clinics for care are not 
representative of the general healthcare seeking population. However, regardless of the 
clinical setting, undiagnosed HIV-infected individuals must seek out healthcare services in 
order to gain access to HIV testing interventions that are housed in clinical facilities. 
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Public Health Significance 
In this analysis, we evaluated an HIV prevention program that was created with a 
very specific purpose in mind: increase HIV testing and HIV case detection in clinical 
settings. Contrary to expectations, we did not observe the intended or expected effects. 
Although HIV testing continued to increase post-intervention, this increase was dwarfed by 
significant levels of pre-intervention HIV testing. Overall, no significant changes in case 
detection or risk of progression to AIDS were observed post-intervention. These unexpected 
results highlight the importance of comprehensively evaluating public health interventions, 
rather than blindly assuming the intervention was successful. No matter how convincing the 
one may find the theoretical basis for an intervention, mathematical simulation models, or 
randomized controlled trials, real-world evaluations of public health interventions are 
irreplaceable. 
We focused on evaluating routine, opt-out HIV testing in the specific population of 
persons seeking clinical care at public STD clinics in North Carolina. Therefore, we cannot 
comment on the impact of this intervention in other clinical settings or geographic regions. A 
universal policy recommended by a national body, like the CDC’s recommendation for 
routine HIV testing, may not perform as expected in all types of clinical settings. This study 
makes an important contribution to the literature by examining the impact of a universal 
policy recommendation in a very specific medical setting. 
STD clinics are unique locations for delivery of HIV prevention services because they 
inherently cater to persons at high risk for HIV acquisition. Pre-intervention, the North 
Carolina STD clinics were very successful at providing HIV testing services to their patient 
population. However, we did observe post-intervention improvements in HIV testing, 
particularly among persons at lower risk for HIV acquisition. 
The high baseline rates of HIV testing in this clinical setting raise important 
substantive and methodological considerations. Due to limitations in our data, we were 
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unable to describe the population of STD clinic patients who were not tested for HIV during 
the study period. Therefore, we do not know if the observed increase in the rate of HIV 
testing among lower-risk persons under the intervention was at the expense of offering HIV 
testing services to higher-risk persons. By promoting routine HIV testing for all persons, 
regardless of risk profile, this intervention may have had the unintended consequence of 
sacrificing HIV testing among higher-risk persons, simply to adhere to the prescribed HIV 
testing protocol. 
Methodologically, the high pre-intervention rates of HIV testing emphasize the 
importance of considering the trajectory of HIV testing in both the pre- and post-intervention 
periods. These trajectories can help public health decision makers to place the intervention 
in context of underlying trends and comprehend the maximum potential benefit of an 
intervention. When we used an aggregate pre-intervention comparison group, our results 
were in agreement with prior studies, identifying an increase in the HIV testing rate and the 
absolute number of HIV cases identified, but a decrease in HIV positivity.7,11,12,49,62 However, 
after adjusting for calendar year, the intervention was associated with a decrease in the rate 
of HIV testing and no change in the rate of case detection. Ignoring underlying temporal 
trajectories oversimplified the impact of the intervention, yielding spurious results. 
Our analytic methods, interrupted time series analysis and multilevel regression 
models, were complementary approaches to addressing correlated observations in our 
complex dataset. Interrupted time series analyses accurately captured underlying temporal 
trends and correlated observations over time, but relied on ecologic monthly cross-sections 
of the study population. Multilevel regression models accounted for correlation between and 
within STD clinics, but could only include crude measures of calendar time. While neither 
method offered a complete picture of HIV testing or case detection, their concurrent use in 
this study shows the potential application of sophisticated epidemiologic methods in the 
evaluation of HIV prevention programs. 
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Just as universal policy recommendations may not have the same effects in different 
clinical settings, their effects may also differ by geographic region. Despite the successes of 
routine, opt-out HIV testing programs in major metropolitan centers like New York City and 
San Francisco, this study is the first to evaluate the translation of these interventions to 
more rural areas of the country. The Southeastern United States bears a disproportionate 
burden of HIV infection and high rates of the many comorbid conditions that facilitate, either 
directly or indirectly, HIV transmission, including: STD infections, socioeconomic and racial 
disparities, stigma, and inadequate access to healthcare services.14,76 HIV infection and 
these comorbid conditions create a complex web of barriers that can complicate the delivery 
of HIV prevention services. This study fills an important gap by evaluation routine, opt-out 
HIV testing in this difficult and oft-ignored region of the United States. 
 
Future Research Directions 
In this study, we identified the importance of considering an HIV prevention 
intervention as a dynamic process, with interplay between the intervention, the undiagnosed 
HIV-infected population the intervention seeks to identify, and STD clinic capacity. We 
suggest the continued evaluation of this intervention for sustainability over a longer post-
intervention period. Such an evaluation would aid in the identification of the maximum 
potential testing levels of an STD clinic. Also, we hypothesize that any slight increases in the 
risk of progression to AIDS observed in the post-intervention period of this study may be 
mitigated when examining a time period further from the initial date of implementation. 
Theoretically, after identifying prevalent HIV cases who may be further along in their disease 
progression, a routine, opt-out HIV testing program would predominantly identify incident 
cases of HIV. We also encourage investigators in other states to replicate our study design 
in different geographies and clinical settings, especially including long pre-intervention 
comparison periods. 
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Data that currently available for analysis did not include information on the larger 
population of patients seeking care in the STD clinics. We would like to examine the impact 
of this intervention in a few select STD clinics in which we could gather denominator data on 
all clinic attendees. These data could be used to track HIV test refusal over time and 
calculate more accurate HIV testing rates based on the denominator of patients attending 
the STD clinic. Data on repeat testers could be used to calculate inter-test intervals, which 
could also be examined as an outcome of this intervention. 
In this study, we categorized late HIV diagnosis by three commonly-used definitions 
based on the time to AIDS. Further research could investigate the impact of this intervention 
on the absolute time to AIDS using proportional hazards regression models. Time to event 
analysis could be completed among persons diagnosed in STD clinics, as well as in a larger 
sample of all persons diagnosed from other clinical sites in North Carolina that implemented 
routine, opt-out HIV testing programs. 
Health departments not only rely on the results of epidemiologic studies to make 
decisions about public health prevention programs, but also on economic analyses. We 
suggest incremental cost-effectiveness and budget impact analyses of this intervention, 
compared with the previous targeted HIV testing strategy. These economic analysis 
methods could then be applied to other clinical settings with HIV testing programs to 
determine the optimal HIV testing strategy for a clinical facility, based on the facility’s patient 
population. 
 
Final Remarks 
 Overall, the introduction of routine, opt-out HIV testing in North Carolina STD clinics 
had minimal impact on HIV testing, case detection, and risk of progression to AIDS. 
However, the lack of a significant impact of this intervention does not imply that the 
intervention should be discontinued. Rather, persons who are not traditionally at risk for HIV 
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infection, but are still at some increased risk by virtue of visiting an STD clinic, reaped the 
greatest benefit from this intervention. The outcomes under study in this analysis were 
bounded quantities and could not increase indefinitely. By expanding HIV testing services, 
we believe that the intervention will eventually allow for a higher set-point of HIV testing to 
be reached than would have been observed without the intervention. Due to the high levels 
of sexual exposure to HIV, we also believe that sustaining this intervention will eventually 
shift from the detection of prevalent HIV cases to identifying incident HIV infection. We 
strongly urge the continued evaluation of this routine, opt-out HIV testing program and other 
HIV prevention programs to assess prolonged population-level impact. 
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Appendix 1: Literature Review of Routine HIV Testing Studies 
 
Table A1.1: Overview of Published Studies Describing HIV Testing Interventions in the 
United States 
Source Setting Location 
Intervention-
Affiliated 
HIV Tests 
New HIV-
Infected  
n (%) 
Clinical 
Outcomes 
Comparison 
Group 
Anaya, 201359 
Primary 
Care 
Veteran's Adm. 
(MA, TX) 4886 14 (0.3%) No 
Yes 
Beckwith, 2007135 Jail RI 95 0 (0%) No No 
Beckwith, 2011136 Jail RI 1343 1 (0.07%) No No 
Beckwith, 2012137 
Jail Baltimore, MD 2066 7 (0.34%) No No 
Jail Philadelphia, PA 27000 75 (0.28%) No No 
Jail Washington, DC 12546 60 (0.48%) No No 
Blackstock, 
201047 
Dental 
Clinic 
New York, NY 3865 19 (0.53%) Yes 
No 
Brooks, 200963 STD Clinic Denver, CO 30405 0.5%-0.8% No Yes 
Brown, 2007138 ED Washington, DC 2486 9 (0.36%) No No 
Brown, 201048 
ED Washington, DC -- 55 Yes No 
ED Oakland, CA -- 114 Yes Yes 
Calderon, 2009139 ED Bronx, NY 6214 57 (0.92%) Yes No 
Campos-Outcalt, 
2006140 
STD Clinic Phoenix, AZ 12176 
68 (0.56%) No No 
CDC,  2007141 
ED Los Angeles, CA 1709 13 (0.8%) No No 
ED New York, NY 1288 19 (1.5%) No No 
ED Oakland, CA 6368 65 (1.0%) No No 
CDC, 201149 Prison WA 5899 6 (0.1%) Yes Yes 
Chen, 2011142 ED (VA) Los Angeles, CA 121 0 (0%) No No 
Christopoulos, 
201050 
ED New York, NY 2569 21 (0.9%) Yes 
No 
Christopoulos, 
201151 
Hospital 
San Francisco, 
CA 
5340 65 (1.1%) Yes Yes 
Christopoulos, 
2013143 ED 
San Francisco, 
CA 9938 46 (0.58%) 
Yes 
No 
Conners, 2012144 
Substance 
Use Veteran's Adm. 414 -- No 
Yes 
Copeland, 201274 ED Atlanta, GA 5610 140 (2.5%) No No 
Cunningham, 
2009145 
Comm. 
Health. 
New York, NY 105 
0 (0%) No No 
Donnell-Fink, 
2012146 ED Boston, MA 1111 2 (0.2%) No No 
Freeman, 200972 ED Augusta, GA 5080 24 (0.47%) No No 
Goetz, 200865 
Health 
System 
Veteran's Adm. 11% 
0.45% No 
Yes 
Goetz, 2009147 
Health 
System 
Veteran's Adm. 
11.60% 0.45% No No 
Hack, 201364 
Pediatric 
ED Newark, NJ 213 0 (0.0%) No 
Yes 
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Table A1.1 (continued): Overview of Published Studies Describing HIV Testing Interventions in 
the United States 
Source Setting Location 
Intervention-
Affiliated HIV 
Tests 
New HIV-
Infected  
n (%) 
Clinical 
Outcomes 
Comparison 
Group 
Halloran, 2012148 
Health 
System Veteran's Admn. 483759 
3972 
(0.8%) No No 
Haukoos, 20107 ED Denver, CO 6702 10 (0.15%) Yes Yes 
Hoxhaj, 201152 ED Houston, TX 14093 80 (0.57%) Yes No 
Hsieh, 2011149 ED Baltimore, MD 2958 44 (1.5%) No No 
Keller, 2011150 STD Clinic Baltimore, MD 5101 34 (0.67%) No No 
Kendrick, 2005151 STD Clinic Chicago, IL 1372 37 (2.7%) No No 
Liang, 2005152 STD Clinic Baltimore, MD 439 18 (4.1%) No No 
Liddicoat, 2006153 Prison Boston, MA 734 2 (0.3%) No Yes 
Lubelchek, 201153 ED Chicago, IL 4755 30 (0.6%) Yes No 
Lyss, 20078 ED Chicago, IL 2824 34 (1.2%)  Yes Yes 
MacGowan, 
200975 
Jail 
FL, LA, NY, WI 
33211 
269 (0.8%) No No 
Maxwell, 2010154 ED Washington, DC 7528 65 (0.9%) No No 
Mehta, 2008155 Hospital Boston, MA 16750 1.37% No No 
Merchant, 2008156 ED Providence, RI 825 0 (0.0%) No No 
Mullins, 2010157 ED Cincinnati, OH 1460 -- No Yes 
Myers, 200961 CHC NC, SC, MI 10769 17 (0.16%) No Yes 
Nayak, 201262 
Hospital 
(VA) Washington, DC 6429 69 (1.1%) No 
Yes 
Scott, 2009158 Hospital Washington, DC 5637 38 (0.67%) No No 
Sattin, 201154 ED Augusta, GA 8504 35 (0.41%) Yes No 
Schrantz, 201155 ED Chicago, IL 1258 28 (2.2%) Yes No 
Siegel, 201056 
Inpatient 
(VA) 
Washington, DC 824 7 (0.85%) Yes Yes 
Silva, 2007159 ED Chicago, IL 1428 10 (0.6%) No No 
Valenti, 2012160 
Primary 
Care 
Detroit, MI 367 1 (0.27%) 
No No 
Walensky, 2005161 
Urgent 
Care 
Boston, MA 2444 48 (2%) 
No 
Yes 
Walensky, 20119 ED Boston, MA 1371 0 (0.0%) Yes No 
Weis, 200973 
Comm. 
Health. 
Aiken, SC 574 0 (0%) 
No No 
White, 200911 ED Oakland, CA 7923 55 (0.7%) Yes Yes 
White, 201012 
ED Oakland, CA 5009 43 (0.9%) Yes Yes 
Urgent 
Care 
Oakland, CA 2914 
12 (0.4%) 
Yes Yes 
White, 201113 ED Oakland, CA 4679 21 (0.4%) Yes Yes 
White, 2011162 ED Oakland, CA 599 10 (1.7%) No No 
Zetola, 2008112 
Health 
System 
San Francisco, 
CA 
4.38/1000 
per month 
8.9/mo - 
14.9/mo 
No Yes 
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Table A1.2: Published Evaluations of Routine HIV Testing Programs with Comparison 
Groups 
 
Source Setting Location Testing Model
HIV Tests
n (% of visits)
New Positive 
n (% of tests)
Intervention: routine, opt-out testing 4886 (13.6%) 14 (0.3%)
Comparison: diagnostic/targeted testing 111 (0.3%) --
Brooks, 2009
63 STD Clinic Denver, CO Intervention: opt-out testing 96% of RPRs 0.7%
Comparison 1: discontinuation of ELISA 92% of RPRs 0.6%
Comparison 2: streamlined consent 86% of RPRs 0.8%
Comparison 3: optional rapid testing 79% of RPRs 0.5%
Intervention: opt-out HIV testing 5899 (90%) 6 (0.1%)
Comparison 1: opt-in HIV testing 4780 (72%) 13 (0.3%)
Comparison 2: request or clinical indication 360 (3.0%) 3 (0.8%)
Intervention: targeted testing 273/month 4/month
Comparison: diagnostic testing 114/month 1.5/month
Intervention: routine, opt-out HIV testing 414 (36.1%) --
Comparison 1: continuation of intervention 246 (28.2%) --
Comparison 2: diagnostic/targeted testing 293 (22.7%) --
Intervention: targeted testing for "at-risk" patients
Site A: 10.8%
Site B: 12.8%
30 (0.5%)
Comparison: diagnostic testing
Site A: 4.8%
Site B: 5.5%
15 (0.5%)
Intervention: routine, opt-in testing 213 (8.1%) 0 (0.0%)
Comparison:  targeted/diagnostic testing 39 (?%) 0 (0.0%)
Intervention: routine testing 6702 (23.9%) 10 (0.2%)
Comparison: diagnostic testing 243 (0.8%) 4 (1.7%)
Intervention: routine testing 734 (73.1%) 2 (0.3%)
Comparison: opt-in testing 318 (18.5%) --
Intervention: routine, opt-out testing 2824 (58.2%) 34 (1.2%)
Comparison: provider-referred testing 414 (95.0%) 48 (11.6%)
Intervention: routine testing of adolescents 1460 (44.6%) --
Comparison 1: post-CDC recommendations, but 
pre-intervention
889 (27.7%) --
Comparison 2: pre-CDC recommendations 378 (12.6%) --
Intervention: routine testing 10769 (18.4%) 17 (0.2%)
Comparison: targeted/diagnostic testing 3078 (3.0%) --
Intervention: routine opt-out testing 6429 (10.3%) 69 (1.1%)
Comparison: targeted testing 3222 (5.5%) 47 (1.5%)
Intervention: routine testing 824 (31.2%) 7 (0.9%)
Comparison: targeted testing 256  (2.6%) 8 (3.1%)
Christopoulos, 
2011
51 Hospital San Francisco, CA
Conners, 
2012
144
Substance 
Use
Veteran's Adm.
Goetz, 2008
65 Health 
System
Veteran's Adm.
Hack, 2013
64 Pediatric ED Newark, NJ
Haukoos, 
2010
7
Anaya, 2013
59 Primary Care
Veteran's Adm. 
(MA, TX)
CDC, 2011
49 Prison WA
ED Denver, CO
Liddicoat, 
2006
153 Prison 0
Lyss, 2007
8 ED Chicago, IL
Mullins, 2010
157 ED Cincinnati, OH
Myers, 2009
61 CHC NC, SC, MI
Nayak, 2012
62 Health 
System (VA)
Washington, DC
Washington, DCInpatient (VA)Siegel, 2010
56
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Table A1.2 (continued): Published Evaluations of Routine HIV Testing Programs with 
Comparison Groups 
 
 
 
 
  
Source Setting Location Testing Model
HIV Tests
n (% of visits)
New Positive 
n (% of tests)
Intervention: routine HIV testing 2444 48 (2%)
Comparison: self-referral clinics 13890 262 (1.9%)
Intervention: routine, opt-in testing 7923 (17.5%) 55 (0.7%)
Comparison: diagnostic testing 1543 (1.6%) 44 (2.9%)
Intervention: routine testing
ED: 5009  (6.7%)
UC: 2914 (7.8%)
ED: 43 (0.9%)
UC: 12 (0.4%)
Comparison: diagnostic testing
ED: 1187 (1.6%)
UC: 342 (0.9%)
ED: 37 (3.1%)
UC: 9 (2.6%)
Intervention; opt-out testing 4679 (20.1%) 21 (0.4%)
Comparison: opt-in testing 4053 (15.2%) 8 (0.2%)
Intervention: no requirement for written consent 17.9/1000 visits 14.9/month
Comparison: separate written consent 13.5/1000 visits 8.9/month
Boston, MAUrgent Care
Walensky, 
2005
161
Zetola, 2008
112 Health 
System
San Francisco, CA
White, 2009
11 ED Oakland, CA
White, 2010
12 ED/Urgent 
Care (UC)
Oakland, CA
White, 2011
13 ED Oakland, CA
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Table A1.2 (continued): Published Evaluations of Routine HIV Testing Programs with 
Comparison Groups Examining Clinical Outcomes 
  
Source Setting Location Testing Model CD4 VL
Intervention: opt-out HIV testing 422 (range: 71-898) --
Comparison 1: opt-in HIV testing -- --
Comparison 2: request or clinical indication -- --
Intervention: targeted testing 268 --
Comparison: diagnostic testing -- --
Intervention: routine testing 69 (IQR: 17-430)
108,790
(IQR: 56,000-153,562)
Comparison: diagnostic testing 13 (IQR: 11-15)
146,000 
(IQR: 50,700-470,000)
Intervention: routine, opt-out testing CD4 <200: 45.2% --
Comparison: provider-referred testing CD4 <200: 82.2% --
Intervention: routine testing 171 (range: 95-679)
48,013 
(range: 1763->500,000)
Comparison: targeted testing -- --
Intervention: routine, opt-in testing 356 (range: 4-1020) --
Comparison: diagnostic testing 99 (range: 9-1224) --
Intervention: routine testing
ED: 195
UC: 381
--
Comparison: diagnostic testing -- --
Intervention; opt-out testing CD4 <200: 48% --
Comparison: opt-in testing CD4 <200: 25% --
White, 2011
13 ED Oakland, CA
White, 2009
11 ED Oakland, CA
White, 2010
12 ED/Urgent 
Care (UC)
Oakland, CA
Siegel, 2010
56 Inpatient (VA) Washington, DC
Lyss, 2007
8 ED Chicago, IL
Haukoos, 
2010
7 ED Denver, CO
Christopoulos, 
2011
51 Hospital San Francisco, CA
CDC, 2011
49 Prison WA
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Table A1.3: Survey-Based and Ecologic Evaluations of Routine HIV Testing Programs 
with Comparison Groups 
   
Source Setting Location Testing Model
HIV Tests
n (% of visits)
CD4
Intervention: legislative change for routine, opt-out 
HIV testing without separate consent (2005)
--
349.8 (IQR: 102-550)
a -- 454.4 (IQR: 190-671)
Intervention: Bronx Knows HIV campaign (2009) 69.30% Concurrent AIDS: 23.6%
Comparison: pre-intervention (2005) 79.10% Concurrent AIDS: 30.1%
Intervention: DC DOH testing campaign (2007) 14.90% --
Comparison: pre-intervention (2005) 18.70% --
Intervention: legislative change for routine, opt-out 
HIV testing without separate consent (2006) 31.4% increase --
Comparison: pre-legislative change (2004) -- --
West-Ojo, 
2010
111 BRFSS Washington, DC
New YorkBRFSSWing, 2009
163
Leeper, 2013
66
HIV clinic Providence, RI
Bronx, NYBRFSSMyers, 2012
67
88 
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Table A2.1: Demographic and Clinic Characteristics of Persons Tested for HIV in 
North Carolina STD Clinics by HIV Test Results, July 2005 through June 2011 
  All Patients Tested New HIV-Infected Not New HIV-Infected 
  n (%) n (%) n (%) 
Intervention       
Pre-Intervention 128029 (31.79) 426 (34.30) 127603 (31.78) 
Post-Intervention 274745 (68.21) 816 (65.70) 273929 (68.22) 
All Tests       
Patient Covariates       
Gender 185714 (46.11) 984 (79.23) 184730 (46.01) 
Male 217060 (53.89) 258 (20.77) 216802 (53.99) 
Female       
Race/Ethnicity 116227 (28.86) 222 (17.87) 116008 (28.89) 
White, NH 228538 (56.74) 830 (66.83) 227708 (56.71) 
Black, NH 35126 (8.72) 81 (6.52) 35045 (8.73) 
Hispanic 22880 (5.68) 109 (8.78) 22771 (5.67) 
Other       
Age (years) 179780 (44.64) 441 (35.51) 179339 (44.66) 
18-24 129717 (32.21) 400 (32.21) 129317 (32.21) 
25-34 57295 (14.23) 232 (18.68) 57063 (14.21) 
35-44 35982 (8.93) 169 (13.61) 35813 (8.92) 
45-64       
Clinic Covariates 300266 (74.55) 992 (79.87) 299274 (74.53) 
Metropolitan Status* 81054 (20.12) 202 (16.26) 80852 (20.14) 
Metropolitan 21454 (5.33) 48 (3.86) 21406 (5.33) 
Micropolitan       
Neither       
Population Density# 135938 (33.75) 300 (24.15) 135638 (33.78) 
<199 81262 (20.18) 197 (15.86) 81065 (20.19) 
200-399 31048 (7.71) 168 (13.53) 30880 (7.67) 
400-599 154526 (38.37) 577 (46.46) 153949 (38.34) 
600+       
% Below Poverty 70298 (17.45) 244 (19.65) 70054 (17.45) 
<15% 250865 (62.28) 783 (63.04) 250082 (62.28) 
15-<20% 59706 (14.82) 159 (12.80) 59547 (14.83) 
20-<25% 21905 (5.44) 56 (4.51) 21849 (5.44) 
25+%       
Affiliated HIV Clinic 83850 (20.82) 354 (28.50) 83496 (20.79) 
Yes 318924 (79.18) 888 (71.50) 318036 (79.21) 
No       
Baseline HIV rate^ 18353 (4.56) 26 (2.09) 18327 (4.56) 
0-5 62317 (15.47) 123 (9.90) 62194 (15.49) 
5-10 78829 (19.57) 175 (14.09) 78654 (19.59) 
10-15 243275 (60.40) 918 (73.91) 242357 (60.36) 
*Defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
^Calculated as the average reported HIV case rate per 100,000 population 2005-2007 
#per square mile 
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Table A2.2: Interrupted Time Series Analysis of the Number of HIV Tests Performed 
per Month in North Carolina STD Clinics, July 2005 through June 2011 
  
Pre-Intervention 
Intercept 
Pre-Intervention 
Slope 
Overall Post-
Intervention Slope 
Slope Attributable to 
Intervention 
  # Tests (95% CI)  MD (95% CI) MD (95% CI) MD (95% CI) 
All Tests 3832 (3613, 4050) 54.69 (40.72, 68.66) 33.75 (25.93, 41.57) -20.94 (-36.95, -4.94) 
Patient Covariates         
Gender         
Male 1893 (1795, 1992) 23.07 (16.78, 29.35) 9.64 (6.12, 13.16) -13.42 (-20.63, -6.22) 
Female 1938 (1802, 2074) 31.67 (22.98, 40.36) 24.23 (19.36, 29.10) -7.44 (-17.39, 2.52) 
Race/Ethnicity         
White, NH 1250 (1167, 1334) 11.44 (6.11, 16.77) 8.10 (5.11, 11.09) -3.34 (-9.45, 2.77) 
Black, NH 1875 (1743, 2008) 41.02 (32.58, 49.46) 23.19 (18.46, 27.91) -17.83 (-27.50, -8.17) 
Hispanic 301 (265, 338) 7.09 (4.78, 9.39) 0.92 (-0.39, 2.22) -6.17 (-8.82, -3.52) 
Other 390 (321, 458) -3.79 (-8.09, 0.51) 1.97 (-0.49, 4.43) 5.76 (0.80, 10.72) 
Age (years)         
18-24 1706 (1614, 1798) 24.29 (18.41, 30.16) 13.42 (10.13, 16.71) -10.87 (-17.59, -4.14) 
25-34 1208 (1127, 1290) 18.33 (13.14, 23.52) 13.39 (10.48, 16.30) -4.94 (-10.89, 1.01) 
35-44 586 (545, 628) 6.57 (3.95, 9.20) 3.83 (2.36, 5.30) -2.74 (-5.76, 0.27) 
45-64 330 (301, 359) 5.57 (3.72, 7.41) 3.21 (2.17, 4.25) -2.35 (-4.47, -0.23) 
Clinic Covariates         
Metropolitan 
Status*         
Metropolitan 2914 (2753, 3076) 38.80 (28.50, 49.11) 26.46 (20.69, 32.23) -12.34 (-24.15, -0.53) 
Micropolitan 744 (679, 809) 12.16 (8.04, 16.28) 5.71 (3.40, 8.02) -6.45 (-11.18, -1.73) 
Neither 173 (152, 193) 3.81 (2.49, 5.13) 1.82 (1.08, 2.57) -1.99 (-3.50, -0.47) 
Population Density#         
<199 1240 (1134, 1347) 19.49 (12.71, 26.27) 10.04 (6.23, 13.85) -9.45 (-17.23, -1.67) 
200-399 817 (769, 865) 8.35 (5.27, 11.44) 11.60 (9.87, 13.33) 3.24 (-0.29, 6.78) 
400-599 309 (255, 364) 5.17 (1.73, 8.61) 3.25 (1.29, 5.21) -1.92 (-5.88, 2.04) 
600+ 1464 (1362, 1566) 21.88 (15.40, 28.37) 9.47 (5.83, 13.10) -12.42 (-19.85, -4.98) 
% Below Poverty         
<15% 664 (615, 713) 12.40 (9.27, 15.53) 7.03 (5.28, 8.79) -5.37 (-8.96, -1.78) 
15-<20% 2447 (2294, 2600) 29.99 (20.25, 39.73) 19.23 (13.77, 24.69) -10.76 (-21.93, 0.40) 
20-<25% 484 (442, 526) 11.18 (8.52, 13.84) 7.25 (5.76, 8.74) -3.93 (-6.98, -0.88) 
25+% 235 (202, 268) 1.36 (-0.74, 3.46) 0.70 (-0.50, 1.90) -0.66 (-3.08, 1.75) 
Affiliated HIV Clinic         
Yes 818 (729, 908) 12.42 (6.76, 18.07) 6.47 (3.27, 9.67) -5.95 (-12.44, 0.55) 
No 3010 (2825, 3196) 42.59 (30.76, 54.42) 27.74 (21.11, 34.37) -14.85 (-28.41, -1.30) 
Baseline HIV rate^       
0-5 184 (165, 204) 1.99 (0.74, 3.24) 2.16 (1.46, 2.86) 0.17 (-1.26, 1.60) 
5-10 592 (553, 631) 9.01 (6.51, 11.50) 7.01 (5.61, 8.40) -2.00 (-4.86, 0.86) 
10-15 830 (772, 888) 6.23 (2.53, 9.93) 8.13 (6.06, 10.21) 1.90 (-2.34, 6.14) 
15+ 2225 (2089, 2361) 37.53 (28.85, 46.21) 16.60 (11.74, 21.46) 
-20.93 (-30.87, -
10.98) 
MD: mean difference, 95% CI: 95% confidence interval 
*Defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
^Calculated as the average reported HIV case rate per 100,000 population 2005-2007 
#per square mile 
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Table A2.3: Interrupted Time Series Analysis of the Rate of HIV Testing per 100,000 
Population per Month in North Carolina STD Clinics, July 2005 through June 2011 
  
Pre-Intervention 
Intercept 
Pre-Intervention 
Slope 
Overall Post-
Intervention Slope 
Slope Attributable to 
Intervention 
  Test Rate (95% CI) MD (95% CI) MD (95% CI) MD (95% CI) 
All Tests 69.59 (65.87, 73.30) 0.81 (0.58, 1.05) 0.46 (0.33, 0.60) -0.35 (-0.62, -0.08) 
Patient Covariates       
Gender         
Male 69.56 (66.20, 72.92) 0.69 (0.48, 0.91) 0.24 (0.12, 0.36) -0.45 (-0.70, -0.21) 
Female 69.61 (65.01, 74.21) 0.93 (0.64, 1.22) 0.68 (0.52, 0.85) -0.25 (-0.58, 0.09) 
Race/Ethnicity         
White 33.09 (30.95, 35.23) 0.25 (0.12, 0.39) 0.19 (0.11, 0.26) -0.06 (-0.22, 0.09) 
Black 162.02 (151.50, 172.55) 2.99 (2.32, 3.66) 1.42 (1.04, 1.79) -1.57 (-2.34, -0.80) 
Hispanic 92.20 (83.48, 100.92) 1.36 (0.80, 0.00) -0.20 (-0.51, 0.12) -1.55 (-2.19, -0.92) 
Other 174.09 (147.58, 200.60) 
-2.26 (-3.93, -
0.58) 0.39 (-0.56, 1.35) 2.65 (0.72, 4.58) 
Age (years)         
18-24 200.14 (190.16, 210.11) 2.45 (1.81, 3.08) 1.10 (0.75, 1.46) -1.34 (-2.07, -0.61) 
25-34 102.03 (95.34, 108.72) 1.47 (1.04, 1.89) 0.92 (0.69, 1.16) -0.54 (-1.03, -0.05) 
35-44 44.92 (41.81, 48.04) 0.44 (0.24, 0.63) 0.33 (0.22, 0.44) -0.10 (-0.33, 0.12) 
45-64 15.27 (14.03, 16.51) 0.19 (0.11, 0.27) 0.09 (0.05, 0.13) -0.10 (-0.19, -0.01) 
Clinic Covariates         
Metropolitan 
Status*         
Metropolitan 75.57 (71.66, 79.49) 0.78 (0.53, 1.03) 0.49 (0.35, 0.63) -0.29 (-0.58, -0.01) 
Micropolitan 61.57 (56.44, 66.69) 0.91 (0.58, 1.24) 0.40 (0.22, 0.58) -0.51 (-0.89, -0.14) 
Neither 38.87 (34.37, 43.36) 0.80 (0.51, 1.08) 0.38 (0.22, 0.54) -0.42 (-0.75, -0.09) 
Population 
Density#         
<199 53.73 (49.32, 58.14) 0.74 (0.46, 1.02) 0.36 (0.20, 0.52) -0.38 (-0.71, -0.06) 
200-399 74.65 (70.52, 78.77) 0.60 (0.33, 0.86) 0.89 (0.75, 1.04) 0.30 (-0.01, 0.60) 
400-599 97.77 (81.06, 114.48) 1.52 (0.47, 2.58) 0.87 (0.27, 1.47) -0.65 (-1.87, 0.56) 
600+ 81.81 (76.70, 86.91) 0.90 (0.58, 1.23) 0.28 (0.09, 0.46) -0.63 (-1.00, -0.25) 
% Below Poverty         
<15% 61.52 (57.35, 65.68) 0.87 (0.60, 1.13) 0.45 (0.30, 0.60) -0.42 (-0.72, -0.11) 
15-<20% 71.54 (67.32, 75.75) 0.71 (0.44, 0.98) 0.40 (0.25, 0.56) -0.30 (-0.61, 0.00) 
20-<25% 66.34 (60.86, 71.83) 1.43 (1.08, 1.78) 0.94 (0.74, 1.13) -0.49 (-0.89, -0.09) 
25+% 84.32 (72.71, 95.93) 0.43 (-0.30, 1.16) 0.21 (-0.21, 0.63) -0.22 (-1.06, 0.62) 
Affiliated HIV 
Clinic         
Yes 69.55 (62.88, 76.22) 0.73 (0.31, 1.16) 0.29 (0.05, 0.53) -0.44 (-0.92, 0.05) 
No 69.50 (65.45, 73.56) 0.84 (0.58, 1.10) 0.52 (0.38, 0.67) -0.32 (-0.62, -0.03) 
Baseline HIV rate^       
0-5 39.68 (35.57, 43.79) 0.40 (0.13, 0.66) 0.45 (0.30, 0.59) 0.05 (-0.25, 0.35) 
5-10 46.07 (43.21, 48.94) 0.58 (0.40, 0.76) 0.46 (0.36, 0.56) -0.12 (-0.33, 0.09) 
10-15 80.45 (75.14, 85.76) 0.46 (0.12, 0.80) 0.65 (0.46, 0.84) 0.19 (-0.20, 0.57) 
15+ 81.57 (76.99, 86.16) 1.11 (0.82, 1.41) 0.38 (0.21, 0.54) -0.74 (-1.07, -0.40) 
MD: mean difference, 95% CI: 95% confidence interval 
*Defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
^Calculated as the average reported HIV case rate per 100,000 population 2005-2007 
#per square mile 
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Table A2.4: Interrupted Time Series Analysis of the Number of New HIV-Infected 
Diagnoses per Month in North Carolina STD Clinics, July 2005 through June 2011 
  
Pre-Intervention 
Intercept 
Pre-Intervention 
Slope 
Overall Post-
Intervention Slope 
Slope Attributable 
to Intervention 
   # Infected (95% CI) MD (95% CI) MD (95% CI) MD (95% CI) 
All Tests 13.82 (10.81, 16.82) 0.10 (-0.09, 0.29) 0.08 (-0.03, 0.19) -0.03 (-0.24, 0.19) 
Patient Covariates       
Gender         
Male 9.34 (7.13, 12) 0.15 (0.01, 0.29) 0.09 (0.01, 0.17) -0.06 (-0.23, 0.10) 
Female 4.48 (3.36, 5.60) -0.05 (-0.12, 0.02) -0.01 (-0.05, 0.03) 0.04 (-0.04, 0.12) 
Race/Ethnicity         
White, NH 2.62 (1.45, 3.80) 0.04 (-0.04, 0.11) 0.01 (-0.03, 0.05) -0.03 (-0.11, 0.06) 
Black, NH 8.83 (6.45, 11.21) 0.04 (-0.12, 0.19) 0.07 (-0.01, 0.16) 0.04 (-0.14, 0.21) 
Hispanic 1.12 (0.26, 1.97) 0.00 (-0.06, 0.05) -0.01 (-0.05, 0.02) -0.01 (-0.08, 0.05) 
Other 1.34 (0.48, 2.19) 0.03 (-0.03, 0.08) 0.01 (-0.02, 0.04) -0.01 (-0.08, 0.05) 
Age (years)         
18-24 4.32 (2.68, 5.96) 0.07 (-0.03, 0.17) 0.08 (0.03, 0.14) 0.01 (-0.11, 0.13) 
25-34 5.00 (3.72, 6.27) -0.02 (-0.10, 0.06) 0.00 (-0.05, 0.04) 0.02 (-0.08, 0.11) 
35-44 3.00 (1.61, 4.40) 0.02 (-0.07, 0.11) 0.03 (-0.02, 0.08) 0.01 (-0.09, 0.11) 
45-64 1.60 (0.49, 2.72) 0.03 (-0.04, 0.10) -0.03 (-0.07, 0.01) -0.06 (-0.14, 0.02) 
Clinic Covariates       
Metropolitan Status*         
Metropolitan 11.45 (8.82, 14.08) 0.09 (-0.08, 0.25) 0.06 (-0.03, 0.16) -0.02 (-0.21, 0.17) 
Micropolitan 2.10 (0.98, 3.22) 0.01 (-0.06, 0.09) 0.02 (-0.02, 0.06) 0.01 (-0.08, 0.09) 
Neither 0.19 (-0.43, 0.82) 0.01 (-0.03, 0.05) -0.01 (-0.03, 0.02) -0.01 (-0.06, 0.03) 
Population Density#         
<199 2.62 (1.31, 3.92) 0.01 (-0.07, 0.10) -0.03 (-0.08, 0.01) -0.05 (-0.14, 0.05) 
200-399 1.75 (0.54, 2.96) 0.06 (-0.02, 0.13) 0.07 (0.03, 0.12) 0.01 (-0.07, 0.10) 
400-599 2.51 (1.36, 3.67) -0.01 (-0.09, 0.06) 0.01 (-0.03, 0.05) 0.03 (-0.06, 0.11) 
600+ 6.81 (4.53, 9.09) 0.05 (-0.09, 0.20) 0.03 (-0.05, 0.11) -0.03 (-0.19, 0.14) 
% Below Poverty         
<15% 1.10 (-0.63, 2.84) 0.18 (0.07, 0.28) 0.01 (-0.05, 0.07) -0.16 (-0.29, -0.04) 
15-<20% 11.19 (8.64, 13.74) -0.10 (-0.26, 0.06) 0.05 (-0.04, 0.14) 0.15 (-0.04, 0.34) 
20-<25% 1.34 (0.48, 2.21) 0.01 (-0.05, 0.06) 0.04 (0.01, 0.07) 0.03 (-0.03, 0.10) 
25+% 0.12 (-0.63, 0.87) 0.03 (-0.02, 0.08) -0.02 (-0.05, 0.01) -0.05 (-0.10, 0.01) 
Affiliated HIV Clinic         
Yes 3.52 (1.66, 5.39) 0.08 (-0.04, 0.20) 0.00 (-0.06, 0.07) -0.08 (-0.21, 0.06) 
No 10.30 (7.60, 13.00) 0.03 (-0.15, 0.20) 0.08 (-0.02, 0.17) 0.05 (-0.15, 0.25) 
Baseline HIV rate^       
0-5 -0.05 (-0.57, 0.48) 0.02 (-0.01, 0.06) 0.00 (-0.01, 0.02) -0.02 (-0.06, 0.02) 
5-10 0.63 (-0.42, 1.68) 0.06 (-0.01, 0.13) 0.01 (-0.02, 0.05) -0.05 (-0.13, 0.03) 
10-15 2.89 (1.47, 4.31) -0.07 (-0.16, 0.02) 0.00 (-0.05, 0.06) 0.07 (-0.03, 0.17) 
15+ 10.38 (7.45, 13.31) 0.08 (-0.10, 0.27) 0.06 (-0.05, 0.16) -0.03 (-0.24, 0.19) 
MD: mean difference, 95% CI: 95% confidence interval 
*Defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
^Calculated as the average reported HIV case rate per 100,000 population 2005-2007 
#per square mile 
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Table A2.5: Interrupted Time Series Analysis of the Rate of New HIV-Infected 
Diagnosis per 1,000 HIV Tests per Month in North Carolina STD Clinics, July 2005 
through June 2011 
  
Pre-Intervention 
Intercept 
Pre-Intervention 
Slope 
Overall Post-
Intervention Slope 
Slope Attributable 
to Intervention 
  
 Positivity Rate 
(95%CI) MD (95% CI) MD (95% CI) MD (95% CI) 
All Tests 3.59 (3.04, 4.13) -0.02 (-0.05, 0.02) 0.00 (-0.02, 0.02) 0.01 (-0.02, 0.05) 
Patient Covariates       
Gender         
Male 5.02 (4.07, 6) 0.01 (-0.05, 0.07) 0.01 (-0.02, 0.05) 0.00 (-0.07, 0.07) 
Female 2.20 (1.73, 2.68) -0.04 (-0.07, -0.01) -0.01 (-0.03, 0.01) 0.03 (0.00, 0.07) 
Race/Ethnicity         
White, NH 2.09 (1.21, 2.97) 0.01 (-0.05, 0.07) 0.00 (-0.03, 0.03) -0.01 (-0.08, 0.05) 
Black, NH 4.58 (3.87, 5.30) -0.05 (-0.10, -0.01) 0.00 (-0.03, 0.02) 0.05 (0.00, 0.10) 
Hispanic 3.44 (1.72, 5.15) -0.04 (-0.15, 0.07) -0.03 (-0.09, 0.03) 0.01 (-0.12, 0.13) 
Other 2.98 (0.31, 5.65) 0.16 (-0.01, 0.33) 0.01 (-0.08, 0.11) -0.14 (-0.34, 0.05) 
Age (years)         
18-24 2.54 (1.74, 3.33) 0.00 (-0.05, 0.05) 0.02 (-0.01, 0.05) 0.01 (-0.04, 0.07) 
25-34 3.97 (3.05, 4.89) -0.05 (-0.11, 0.01) -0.02 (-0.05, 0.01) 0.03 (-0.04, 0.10) 
35-44 5.20 (3.64, 6.76) -0.03 (-0.13, 0.07) 0.01 (-0.04, 0.07) 0.04 (-0.07, 0.15) 
45-64 4.74 (2.59, 6.90) 0.00 (-0.13, 0.14) -0.08 (-0.16, -0.01) -0.09 (-0.25, 0.07) 
Clinic Covariates         
Metropolitan Status*         
Metropolitan 3.88 (3.22, 4.54) -0.02 (-0.06, 0.03) 0.00 (-0.03, 0.02) 0.01 (-0.04, 0.06) 
Micropolitan 3.02 (1.68, 4.36) -0.03 (-0.12, 0.05) 0.00 (-0.05, 0.05) 0.03 (-0.07, 0.13) 
Neither 1.29 (-0.62, 3.20) 0.00 (-0.12, 0.12) -0.02 (-0.09, 0.05) -0.02 (-0.16, 0.12) 
Population Density#         
<199 2.21 (1.31, 3.12) -0.02 (-0.08, 0.04) -0.03 (-0.06, 0.01) 0.00 (-0.07, 0.06) 
200-399 2.12 (1.01, 3.24) 0.04 (-0.03, 0.11) 0.04 (0.00, 0.08) -0.01 (-0.09, 0.08) 
400-599 
7.58 (4.96, 
10.20) -0.11 (-0.28, 0.05) -0.01 (-0.10, 0.08) 0.10 (-0.09, 0.29) 
600+ 4.65 (3.73, 5.56) -0.03 (-0.08, 0.03) 0.00 (-0.04, 0.03) 0.02 (-0.04, 0.09) 
% Below Poverty         
<15% 2.32 (0.85, 3.79) 0.12 (0.03, 0.22) -0.01 (-0.07, 0.04) -0.14 (-0.24, -0.03) 
15-<20% 4.38 (3.66, 5.10) -0.07 (-0.11, -0.02) 0.00 (-0.03, 0.02) 0.06 (0.01, 0.12) 
20-<25% 3.01 (1.67, 4.36) -0.04 (-0.13, 0.04) 0.02 (-0.03, 0.07) 0.07 (-0.03, 0.16) 
25+% 0.65 (-1.49, 2.78) 0.10 (-0.04, 0.23) -0.06 (-0.14, 0.01) -0.16 (-0.32, -0.01) 
Affiliated HIV Clinic         
Yes 4.52 (3.05, 5.99) 0.01 (-0.09, 0.10) -0.02 (-0.07, 0.04) -0.02 (-0.13, 0.09) 
No 3.33 (2.74, 3.92) -0.03 (-0.06, 0.01) 0.00 (-0.02, 0.02) 0.03 (-0.02, 0.07) 
Baseline HIV rate^       
0-5 0.01 (-2.10, 2.11) 0.10 (-0.04, 0.23) 0.00 (-0.07, 0.08) -0.10 (-0.25, 0.06) 
5-10 1.05 (-0.29, 2.38) 0.07 (-0.02, 0.15) 0.00 (-0.05, 0.05) -0.07 (-0.17, 0.03) 
10-15 3.35 (2.16, 4.53) -0.08 (-0.16, -0.01) -0.01 (-0.05, 0.03) 0.07 (-0.01, 0.16) 
15+ 4.64 (3.91, 5.38) -0.03 (-0.08, 0.02) 0.00 (-0.03, 0.03) 0.03 (-0.02, 0.08) 
MD: mean difference, 95 CI: 95% confidence intervanl 
*Defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
^Calculated as the average reported HIV case rate per 100,000 population 2005-2007 
#per square mile 
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Figure A2.1(a-aa): Results of Interrupted Time Series Analysis in North Carolina STD 
Clinics, July 1, 2005 through June 30, 2011, Stratified by Patient and Clinic 
Characteristics 
Figure A2.1(a): Men 
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Figure A2.1(b): Women 
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Figure A2.1(c): Non-Hispanic Whites 
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Figure A2.1(d): Non-Hispanic Blacks 
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Figure A2.1(e): Hispanics 
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Figure A2.1(f): Other Race/Ethnicities 
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Figure A2.1(g): Aged 18-24 
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Figure A2.1(h): Aged 25-34 
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Figure A2.1(i): Aged 35-44 
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Figure A2.1(j): Aged 45-64 
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Figure A2.1(k): Clinics in Metropolitan Statistical Areas 
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Figure A2.1(l): Clinics in Micropolitan Statistical Areas 
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Figure A2.1(m): Clinics in Neither Metropolitan nor Micropolitan Statistical Areas 
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Figure A2.1(n): Clinics in Counties of Population Density <199 Persons per Square Mile 
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Figure A2.1(o): Clinics in Counties of Population Density 200-399 Persons per Square 
Mile 
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Figure A2.1(p): Clinics in Counties of Population Density 400-500 Persons per Square 
Mile 
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Figure A2.1(q): Clinics in Counties of Population Density ≥600 Persons per Square Mile 
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Figure A2.1(r): Clinics in Counties with <15% of the Population Below the Poverty Line 
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Figure A2.1(s): Clinics in Counties with 15-19.9% of the Population Below the Poverty 
Line 
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Figure A2.1(t): Clinics in Counties with 20-24.9% of the Population Below the Poverty 
Line 
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Figure A2.1(u): Clinics in Counties with ≥25% of the Population Below the Poverty Line 
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Figure A2.1(v): Clinics with an In-House HIV Clinic 
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Figure A2.1(w): Clinics without an In-House HIV Clinic 
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Figure A2.1(x): Clinics in Counties with Baseline HIV Case Rate of 0-4.9 per 100,000 
Population 
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Figure A2.1(y): Clinics in Counties with Baseline HIV Case Rate of 5-9.9 per 100,000 
Population 
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Figure A2.1(z): Clinics in Counties with Baseline HIV Case Rate of 10-14.9 per 100,000 
Population 
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Figure A2.1(aa): Clinics in Counties with Baseline HIV Case Rate of ≥15 per 100,000 
Population 
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Table A2.6: Sensitivity Analysis: Comparison of Lag Periods (0 months, 3 months, 6 
months) on Interrupted Time Series Results for HIV Testing and Case Detection 
Outcomes 
  Pre-Intervention 
Overall  
Post-Intervention 
Attributable to 
Intervention 
  MD (95% CI)* MD (95% CI)* MD (95% CI)* 
Number of HIV Tests       
No Lag 54.11 (37.36, 70.86) 40.66 (32.20, 49.11) -13.45 (-32.13, 5.24) 
3 Month Lag 54.69 (40.72, 68.66) 33.75 (25.93, 41.57) -20.94 (-36.95, -4.94) 
6 Month Lag 54.83 (40.81, 68.84) 33.76 (24.96, 42.57) -21.06 (-37.61, -4.52) 
        
Rate of HIV Testing per 
100,000 Population       
No Lag 0.84 (0.56, 1.12) 0.57 (0.42, 0.71) -0.27 (-0.59, 0.05) 
3 Month Lag 0.81 (0.58, 1.05) 0.46 (0.33, 0.60) -0.35 (-0.62, -0.08) 
6 Month Lag 0.82 (0.58, 1.05) 0.46 (0.31, 0.61) -0.36 (-0.64, -0.07) 
        
Number of HIV-Infections       
No Lag 0.10 (-0.09, 0.29) 0.10 (0.00, 0.20) 0.00 (-0.21, 0.21) 
3 Month Lag 0.10 (-0.09, 0.29) 0.08 (-0.03, 0.19) -0.03 (-0.24, 0.19) 
6 Month Lag 0.10 (-0.09, 0.30) 0.09 (-0.04, 0.21) -0.02 (-0.25, 0.21) 
        
Rate of HIV-Positivity per 
1,000 Tests       
No Lag -0.02 (-0.05, 0.02) 0.00 (-0.02, 0.01) 0.01 (0.00, 0.05) 
3 Month Lag -0.02 (-0.05, 0.02) 0.00 (-0.02, 0.02) 0.01 (-0.02, 0.05) 
6 Month Lag -0.02 (-0.05, 0.02) 0.00 (-0.02, 0.02) 0.02 (-0.02, 0.06) 
*MD: mean difference, 95% CI: 95% confidence interval 
Bold: base case scenario 
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Table A2.7: Intercensal Population Estimates, 2005-2011 
 
*Defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
^Calculated as the average reported HIV case rate per 100,000 population 2005-2007 
#per square mile 
  
2005 2006 2007 2008 2009 2010 2011
Overall 5,519,921  5,651,861  5,767,073  5,877,799  5,955,804  6,025,081  6,076,089  
Gender
Male 2,721,668  2,788,186  2,832,321  2,888,829  2,922,520  2,957,715  2,980,145  
Female 2,798,253  2,863,675  2,934,752  2,988,970  3,033,284  3,067,366  3,095,944  
Race/Ethnicity
White 3,779,507  3,842,024  3,890,934  3,931,518  3,953,351  3,971,835  3,983,752  
Black 1,163,462  1,194,311  1,222,168  1,250,609  1,273,130  1,293,847  1,311,611  
Hisp 331,213      354,463      377,358      403,755      423,092      440,503      450,392      
Other 222,491      235,055      247,397      259,988      271,112      281,528      290,296      
Age (years)
18-24 847,897      874,719      881,226      901,791      916,011      927,628      939,829      
25-34 1,187,065  1,192,318  1,201,650  1,223,875  1,237,192  1,254,196  1,262,635  
35-44 1,307,014  1,326,333  1,342,822  1,347,032  1,336,480  1,324,496  1,316,460  
45-64 2,177,945  2,258,491  2,341,375  2,405,101  2,466,121  2,518,761  2,557,165  
Metropolitan Status*
Metropolitan 3,866,718  3,976,406  4,072,924  4,164,999  4,232,414  4,290,295  4,350,692  
Micropolitan 1,209,927  1,226,883  1,240,785  1,255,810  1,264,050  1,273,688  1,277,319  
Neither 445,344      450,654      455,515      459,136      461,502      463,223      462,011      
Population Density
#
<199 2,312,142  2,352,558  2,385,196  2,417,870  2,437,836  2,461,135  2,464,184  
200-399 1,096,360  1,119,612  1,142,663  1,163,101  1,175,948  1,186,362  1,198,801  
400-599 315,463      320,475      322,295      326,929      331,296      333,399      337,642      
600+ 1,798,024  1,861,298  1,919,069  1,972,044  2,012,885  2,046,311  2,089,395  
% Below Poverty Line
<15% 1,085,677  1,127,720  1,167,253  1,201,416  1,224,891  1,245,853  1,261,929  
15-<20% 3,426,561  3,505,672  3,571,876  3,637,433  3,686,387  3,728,244  3,786,094  
20-<25% 730,682      740,230      747,374      756,502      760,277      765,204      755,491      
25+% 279,069      280,320      282,720      284,594      286,409      287,905      286,508      
Affiliated HIV Clinic
Yes 1,184,289  1,232,826  1,278,948  1,321,812  1,355,406  1,381,556  1,412,691  
No 4,337,700  4,421,117  4,490,276  4,558,133  4,602,559  4,645,650  4,677,331  
Baseline HIV Rate
^
0-5 464,178      468,982      471,482      474,363      476,057      477,178      476,010      
5-10 1,286,784  1,319,251  1,345,695  1,370,263  1,381,777  1,394,504  1,398,344  
10-15 1,033,586  1,050,743  1,069,678  1,087,349  1,099,117  1,109,906  1,119,654  
15+ 2,737,441  2,814,968  2,882,369  2,947,970  3,001,013  3,045,619  3,096,014  
Intercensal Population Estimates
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Table A2.8: Sensitivity Analysis: Comparison of Fixed Effects Models and County-
Specific Random Intercept Multilevel Models on HIV Positivity, Adjusted for Patient 
and Clinic Covariate Sets and Calendar Year of Testing 
  
County-Specific  
Random Intercept Fixed Effects Only 
  OR (95% CI)* OR (95% CI)* 
Unadjusted     
Post-Intervention 0.90 (0.80, 1.01) 0.89 (0.79, 1.00) 
Pre-Intervention 1.00 1.00 
Patient Covariates^     
Post-Intervention 0.92 (0.82, 1.04) 0.93 (0.82, 1.05) 
Pre-Intervention 1.00 1.00 
Clinic Covariates#     
Post-Intervention 0.90 (0.80, 1.01) 0.90 (0.80, 1.02) 
Pre-Intervention 1.00 1.00 
Patient + Clinic Covariates     
Post-Intervention 0.92 (0.82, 1.04) 0.93 (0.82, 1.05) 
Pre-Intervention 1.00 1.00 
      
Year     
Post-Intervention 1.13 (0.57, 2.23) 1.18 (0.60, 2.31) 
Pre-Intervention 1.00 1.00 
Patient Covariates + Year     
Post-Intervention 1.16 (0.59, 2.28) 1.18 (0.60, 2.32) 
Pre-Intervention 1.00 1.00 
Clinic Covariates + Year     
Post-Intervention 1.12 (0.57, 2.21) 1.13 (0.58, 2.22) 
Pre-Intervention 1.00 1.00 
Patient + Clinic Covariates + Year   
Post-Intervention 0.92 (0.82, 1.04) 1.16 (0.59, 2.28) 
Pre-Intervention 1.00 1.00 
*OR: odds ratio, 95% CI: 95% confidence interval 
^Patient covariates include gender, race/ethnicity, and age 
#Clinic covariates include metropolitan status, population density, % below poverty line, affiliated HIV clinic, and 
baseline HIV rate 
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Table A2.9: Sensitivity Analysis: Comparison of Lag Periods (0 months, 3 months, 6 
months) on Multilevel Model Results on HIV Positivity, Adjusted for Patient and Clinic 
Covariate Sets and Calendar Year of Testing 
  Base Case   Alternative Lags 
 3-Month Lag  No Lag 6-Month Lag 
  OR (95% CI)*   OR (95% CI)* OR (95% CI)* 
Unadjusted     
Post-Intervention 0.90 (0.80, 1.01)  0.90 (0.80, 1.01) 0.89 (0.79, 1.01) 
Pre-Intervention 1.00  1.00 1.00 
Patient Covariates^     
Post-Intervention 0.92 (0.82, 1.04)  0.92 (0.82, 1.04) 0.92 (0.81, 1.04) 
Pre-Intervention 1.00  1.00 1.00 
Clinic Covariates#     
Post-Intervention 0.90 (0.80, 1.01)  0.90 (0.80, 1.01) 0.90 (0.79, 1.01) 
Pre-Intervention 1.00  1.00 1.00 
Patient + Clinic Covariates     
Post-Intervention 0.92 (0.82, 1.04)  0.92 (0.82, 1.04) 0.92 (0.82, 1.04) 
Pre-Intervention 1.00  1.00 1.00 
     
Year     
Post-Intervention 1.13 (0.57, 2.23)  1.02 (0.69, 1.52) 0.89 (0.54, 1.46) 
Pre-Intervention 1.00  1.00 1.00 
Patient Covariates + Year     
Post-Intervention 1.16 (0.59, 2.28)  1.04 (0.70, 1.54) 0.92 (0.56, 1.51) 
Pre-Intervention 1.00  1.00 1.00 
Clinic Covariates + Year     
Post-Intervention 1.12 (0.57, 2.21)  1.02 (0.68, 1.51) 0.88 (0.54, 1.45) 
Pre-Intervention 1.00  1.00 1.00 
Patient + Clinic Covariates + Year     
Post-Intervention 0.92 (0.82, 1.04)  1.03 (0.69, 1.53) 0.91 (0.55, 1.50) 
Pre-Intervention 1.00   1.00 1.00 
*OR: odds ratio, 95% CI: 95% confidence interval 
^Patient covariates include gender, race/ethnicity, and age 
#Clinic covariates include metropolitan status, population density, % below poverty line, affiliated HIV clinic, and 
baseline HIV rate 
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Appendix 3: Aim 2 Supplemental Tables and Figures 
 
Table A3.1: Demographic and Clinic Characteristics of Persons Tested for HIV in 
North Carolina STD Clinics by Risk of Progression to AIDS within 12 Months of Initial 
HIV Diagnosis, July 2005 through June 2011 
  All New Infections 
AIDS within  
12 months 
No AIDS within  
12 months 
  n (%) n (%) n (%) 
Intervention       
Pre-Intervention 422 (35.08) 52 (33.77) 370 (35.27) 
Post-Intervention 781 (64.92) 102 (66.23) 679 (64.73) 
Patient Characteristics       
Gender       
Male 952 (79.14) 121 (78.57) 831 (79.22) 
Female 251 (20.86) 33 (21.43) 218 (20.78) 
Race/Ethnicity       
White 214 (17.79) 23 (14.94) 191 (18.21) 
Black 803 (66.75) 106 (68.83) 697 (66.44) 
Hisp 78 (6.48) 13 (8.44) 65 (6.20) 
Other 108 (8.98) 12 (7.79) 96 (9.15) 
Age (years)       
18-24 429 (35.66) 47 (30.52) 382 (36.42) 
25-34 386 (32.09) 48 (31.17) 338 (32.22) 
35-44 225 (18.70) 27 (17.53) 198 (18.88) 
45-64 163 (13.55) 32 (20.78) 131 (12.49) 
Previous Test       
Yes 347 (28.84) 61 (39.61) 286 (27.26) 
No 856 (71.16) 93 (60.39) 763 (72.74) 
Gender/Risk       
Female 251 (20.86) 33 (21.43) 218 (20.78) 
Male Heterosexual 417 (34.66) 60 (38.96) 357 (34.03) 
MSM 535 (44.47) 61 (39.61) 474 (45.19) 
Clinic Characteristics       
Metropolitan Status*       
Metropolitan 958 (79.63) 114 (74.03) 844 (80.46) 
Micropolitan 198 (16.46) 30 (19.48) 168 (16.02) 
Neither 47 (3.91) 10 (6.49) 37 (3.53) 
Population Density#       
<199 297 (24.69) 51 (33.12) 246 (23.45) 
200-399 191 (15.88) 21 (13.64) 170 (16.21) 
400-599 163 (13.55) 18 (11.69) 145 (13.82) 
600+ 552 (45.89) 64 (41.56) 488 (46.52) 
% Below Poverty Line       
<15% 234 (19.45) 34 (22.08) 200 (19.07) 
15-<20% 755 (62.76) 84 (54.55) 671 (63.97) 
20-<25% 158 (13.13) 23 (14.94) 135 (12.87) 
25+% 56 (4.66) 13 (8.44) 43 (4.10) 
Affiliated HIV Clinic       
Yes 863 (71.74) 113 (73.38) 750 (71.50) 
No 340 (28.26) 41 (26.62) 299 (28.50) 
Baseline HIV Rate^       
0-10 145 (12.05) 16 (10.39) 129 (12.30) 
10-15 173 (14.38) 26 (16.88) 147 (14.01) 
15+ 885 (73.57) 112 (72.73) 773 (73.69) 
*Defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
^Calculated as the average reported HIV case rate per 100,000 population 2005-2007 
#per square mile 
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Table A3.2: Sensitivity Analysis: Impact of Adjusting for Calendar Year of HIV Testing 
on Associations between the Expanded HIV Testing Program and Risk of Progression 
to AIDS using County-Specific Random Intercept Regression Models 
  Base Definition   Alternate Definitions 
  
AIDS within 12 
months   
AIDS within 1 
month 
AIDS within 6 
months 
AIDS within 18 
months 
  RR (95% CI)*   RR (95% CI)* RR (95% CI)* RR (95% CI)* 
Unadjusted           
Post-Intervention 1.05 (0.77, 1.43)   1.23 (0.75, 2.01) 0.95 (0.67, 1.33) 0.97 (0.72, 1.29) 
Pre-Intervention 1.00   1.00 1.00 1.00 
Patient Covariates^           
Post-Intervention 0.99 (0.72, 1.36)   1.19 (0.72, 1.95) 0.91 (0.65, 1.29) 0.91 (0.68, 1.21) 
Pre-Intervention 1.00   1.00 1.00 1.00 
Clinic Covariates#           
Post-Intervention 1.01 (0.74, 1.39)   1.22 (0.74, 2.01) 0.91 (0.65, 1.28) 0.93 (0.69, 1.24) 
Pre-Intervention 1.00   1.00 1.00 1.00 
Patient + Clinic Covariates           
Post-Intervention 0.96 (0.70, 1.32)   1.17 (0.70, 1.94) 0.89 (0.63, 1.25) 0.87 (0.65, 1.17) 
Pre-Intervention 1.00   1.00 1.00 1.00 
            
Year           
Post-Intervention 0.39 (0.05, 2.86)   1.04 (0.13, 8.15) 0.43 (0.06, 3.11) 0.69 (0.17, 2.82) 
Pre-Intervention 1.00   1.00 1.00 1.00 
Patient Covariates + Year           
Post-Intervention 0.40 (0.06, 2.91)   1.01 (0.13, 7.90) 0.41 (0.06, 3.00) 0.72 (0.18, 2.93) 
Pre-Intervention 1.00   1.00 1.00 1.00 
Clinic Covariates + Year           
Post-Intervention 0.41 (0.06, 3.00)   1.20 (0.15, 9.38) 0.46 (0.06, 3.37) 0.72 (0.18, 2.94) 
Pre-Intervention 1.00   1.00 1.00 1.00 
Patient + Clinic Covariates 
+ Year           
Post-Intervention 0.45 (0.06, 3.43)  1.24 (0.15, 10.36) 0.48 (0.06, 3.69) 0.79 (0.18, 3.48) 
Pre-Intervention 1.00   1.00 1.00 1.00 
*RR = risk ratio for progression to AIDS within specified time period for persons diagnosed after the introduction 
of a routine HIV testing intervention (exposed) vs. before (unexposed) 
^Patient covariates include gender, race/ethnicity, age, and self-reported previous HIV test 
#Clinic covariates include metropolitan status, population density, % below poverty line, affiliated HIV clinic, and 
baseline HIV rate 
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Table A3.4: Sensitivity Analysis: Comparison of Fixed and County-Specific Random 
Intercept Regression Models on Associations between the Expanded HIV Testing 
Program and Risk of Progression to AIDS 
  Random Intercept Fixed Effects 
  RR (95% CI)* RR (95% CI)* 
Base Definition   
12 months   
Unadjusted   
Post-Intervention 1.05 (0.77, 1.43) 1.06 (0.78, 1.45) 
Pre-Intervention 1.00 1.00 
Patient Covariates^   
Post-Intervention 0.99 (0.72, 1.36) 1.00 (0.73, 1.37) 
Pre-Intervention 1.00 1.00 
Clinic Covariates#   
Post-Intervention 1.01 (0.74, 1.39) 1.01 (0.74, 1.39) 
Pre-Intervention 1.00 1.00 
Patient + Clinic Covariates   
Post-Intervention 0.96 (0.70, 1.32) 0.96 (0.70, 1.32) 
Pre-Intervention 1.00 1.00 
Alternative Definitions   
1 month   
Unadjusted   
Post-Intervention 1.23 (0.75, 2.01) 1.26 (0.77, 2.07) 
Pre-Intervention 1.00 1.00 
Patient Covariates   
Post-Intervention 1.19 (0.72, 1.95) 1.17 (0.71, 1.93) 
Pre-Intervention 1.00 1.00 
Clinic Covariates   
Post-Intervention 1.22 (0.74, 2.01) 1.23 (0.75, 2.02) 
Pre-Intervention 1.00 1.00 
Patient + Clinic Covariates   
Post-Intervention 1.17 (0.70, 1.94) 1.17 (0.70, 1.95) 
Pre-Intervention 1.00 1.00 
6 months   
Unadjusted   
Post-Intervention 0.95 (0.67, 1.33) 0.95 (0.68, 1.34) 
Pre-Intervention 1.00 1.00 
Patient Covariates   
Post-Intervention 0.91 (0.65, 1.29) 0.92 (0.65, 1.29) 
Pre-Intervention 1.00 1.00 
Clinic Covariates   
Post-Intervention 0.91 (0.65, 1.28) 0.91 (0.65, 1.28) 
Pre-Intervention 1.00 1.00 
Patient + Clinic Covariates   
Post-Intervention 0.89 (0.63, 1.25) 0.89 (0.63, 1.25) 
Pre-Intervention 1.00 1.00 
18 months   
Unadjusted   
Post-Intervention 0.97 (0.72, 1.29) 0.97 (0.73, 1.30) 
Pre-Intervention 1.00 1.00 
Patient Covariates   
Post-Intervention 0.91 (0.68, 1.21) 0.91 (0.68, 1.22) 
Pre-Intervention 1.00 1.00 
Clinic Covariates   
Post-Intervention 0.93 (0.69, 1.24) 0.93 (0.69, 1.24) 
Pre-Intervention 1.00 1.00 
Patient + Clinic Covariates   
Post-Intervention 0.87 (0.65, 1.17) 0.87 (0.65, 1.17) 
Pre-Intervention 1.00 1.00 
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*RR = risk ratio for progression to AIDS within 12 months for persons diagnosed after the introduction of a 
routine HIV testing intervention (exposed) vs. before (unexposed) 
^Patient covariates include gender, race/ethnicity, age, and self-reported previous HIV test 
#Clinic covariates include metropolitan status, population density, % below poverty line, affiliated HIV clinic, and 
baseline HIV rate  
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Table A3.5: Sensitivity Analysis: Comparison of Lag Periods (0 months, 3 months, 
and 6 months) on Associations between the Expanded HIV Testing Program and Risk 
of Progression to AIDS 
  Base Case Lag   Alternative Lags 
 No Lag  3-Month Lag 6-Month Lag 
  RR (95% CI)*   RR (95% CI)* RR (95% CI)* 
Base Definition     
12 months     
Post-Intervention 1.05 (0.77, 1.43)  1.03 (0.75, 1.42) 1.06 (0.77, 1.47) 
Pre-Intervention 1.00  1.00 1.00 
Alternative Definitions     
1 month     
Post-Intervention 1.23 (0.75, 2.01)  1.23 (0.74, 2.05) 1.25 (0.75, 2.09) 
Pre-Intervention 1.00  1.00 1.00 
6 months     
Post-Intervention 0.91 (0.65, 1.28)  0.95 (0.67, 1.34) 0.97 (0.68, 1.37) 
Pre-Intervention 1.00  1.00 1.00 
18 months     
Post-Intervention 0.97 (0.72, 1.29)  0.93 (0.69, 1.26) 0.94 (0.70, 1.27) 
Pre-Intervention 1.00   1.00 1.00 
*RR = risk ratio for progression to AIDS within specified time period for persons diagnosed after the introduction 
of a routine HIV testing intervention (exposed) vs. before (unexposed) 
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Table A3.6: Association between the Expanded HIV Testing Program and Risk of 
Progression to AIDS, Stratified by Clinic-Level Characteristics 
 Base Definition  Alternative Definitions 
  
AIDS within 12 
months   
AIDS within 1 
month 
AIDS within 6 
months 
AIDS within 18 
months 
  RR (95% CI)   RR (95% CI) RR (95% CI) RR (95% CI) 
Unadjusted           
Post-Intervention 1.05 (0.77, 1.43)   1.23 (0.75, 2.01) 0.95 (0.67, 1.33) 0.97 (0.72, 1.29) 
Pre-Intervention 1.00   1.00 1.00 1.00 
Clinic Characteristics           
Metropolitan Status*           
Metropolitan 1.06 (0.74, 1.52)   1.17 (0.67, 2.04) 0.94 (0.64, 1.40) 0.98 (0.70, 1.37) 
Micropolitan 1.11 (0.54, 2.28)   2.34 (0.53, 10.43) 1.07 (0.49, 2.32) 0.95 (0.49, 1.84) 
Neither 0.48 (0.16, 1.49)   0.43 (0.09, 1.95) 0.41 (0.13, 1.33) 0.55 (0.18, 1.63) 
Population Density#           
<199 0.94 (0.54, 1.64)   1.74 (0.61, 4.94) 0.98 (0.53, 1.80) 0.97 (0.57, 1.66) 
200-399 0.95 (0.41, 2.19)   0.47 (0.13, 1.69) 0.67 (0.25, 1.78) 0.82 (0.39, 1.76) 
400-599 0.82 (0.34, 1.98)   *NE 0.67 (0.25, 1.83) 0.74 (0.32, 1.71) 
≥600 1.16 (0.71, 1.88)   1.16 (0.60, 2.28) 1.01 (0.60, 1.69) 1.01 (0.65, 1.57) 
% Below Poverty Line           
<15% 1.27 (0.66, 2.45)   1.59 (0.57, 4.43) 1.19 (0.57, 2.48) 1.02 (0.56, 1.86) 
15-19.9% 0.96 (0.63, 1.46)   1.12 (0.59, 2.12) 0.87 (0.56, 1.35) 0.93 (0.63, 1.38) 
20-24.9% 1.61 (0.58, 4.45)   1.56 (0.36, 6.85) 1.18 (0.41, 3.37) 1.19 (0.52, 2.73) 
≥25% 0.54 (0.21, 1.38)   0.32 (0.02, 4.95) 0.58 (0.20, 1.72) 0.60 (0.24, 1.49) 
Affiliated HIV Clinic           
Yes 1.30 (0.70, 2.42)   2.31 (0.66, 8.09) 1.11 (0.57, 2.16) 1.10 (0.63, 1.90) 
No 0.96 (0.67, 1.38)   1.05 (0.61, 1.81) 0.89 (0.60, 1.32) 0.92 (0.65, 1.29) 
Baseline HIV Rate^           
<10 0.64 (0.25, 1.61)   0.50 (0.15, 1.67) 0.71 (0.24, 2.12) 0.62 (0.26, 1.47) 
10-14.9 1.05 (0.49, 2.28)   1.15 (0.23, 5.75) 0.77 (0.34, 1.74) 1.12 (0.52, 2.41) 
≥15 1.13 (0.78, 1.63)   1.50 (0.83, 2.71) 1.03 (0.69, 1.53) 1.00 (0.71, 1.41) 
RR = risk ratio for progression to AIDS within specified time period for persons diagnosed after the introduction of 
a routine HIV testing intervention (exposed) vs. before (unexposed), not adjusted for patient- or clinic-level 
covariates 
*Defined by the US Census Bureau’s metropolitan and micropolitan statistical areas 
^Calculated as the average reported HIV case rate per 100,000 population 2005-2007 
#per square mile 
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Table A3.7: Absolute Risks of HIV (per 1000 Tests) and Progression to AIDS within 12 
months for Women over the Study Period (July 1, 2005 through June 30, 2011) 
  Risk of HIV per 1000 Tests 
Risk of Progression to AIDS 
 within 12 months 
  (95% CI) (95% CI) 
2005 2.20 (1.37, 3.02) 14.81 (1.23, 28.40) 
2006 1.67 (1.18, 2.15) 4.44 (-1.62, 10.51) 
2007 1.42 (1.01, 1.83) 4.55 (-1.65, 10.75) 
2008 0.97 (0.65, 1.28) 29.41 (13.99, 44.83) 
2009 1.22 (0.81, 1.56) 18.37 (7.47, 29.27) 
2010 1.36 (0.55, 1.08) 8.82 (-0.76, 18.41) 
2011 0.81 (0.45, 1.17) 16.67 (-0.74, 34.06) 
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